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CHARACTERIZATION AND MODELING OF ACTIVATED SLUDGE 
PROCESS FOR PHARMACEUTICAL INDUSTRY WASTEWATERS 
SUMMARY 
Since the 1990s water contamination by pharmaceuticals has been an environmental 
issue of concern. Most pharmaceuticals are deposited in the environment through 
human consumption and excretion, and are often filtered ineffectively by wastewater 
treatment plants which are not designed to manage them. During the past decade, 
concern has grown about the adverse effects the use and disposal of pharmaceuticals 
might potentially have on human and ecological health. Research has shown that 
after passing through wastewater treatment, pharmaceuticals, amongst other 
compounds, are released directly into the environment.Among all other 
pharmaceutical drugs and substances, antibiotics are one of the major groups of 
pharmaceuticals. Little is known about the extent of environmental occurrence, 
transport, and ultimate fate and effects of pharmaceuticals in general, as well as of 
antibiotics in particular. Therefore, the adverse effect of the environment and health 
brought from the processing and disposal of these products become important issue 
in the field of environmental engineering. 
Antibiotics are industrially produced and commercially used, but they are not 
required to undergo the extensive level of testing for possible environmental impact. 
For this reason, these substances are becoming an increasingly large problem in 
WWTP‘s, they also spoil ecological balance to form toxicity to organisms in 
ecosystem and biological treatment systems. 
Pharmaceutical industry formulation subcategory includes tablet, capsulle, liquid or 
pomad production and produced in requested dosage forms. It‘s important to 
determine wastewater sources, characterizations and volumes generated from this 
subcategory. In this thesis,  It is  aimed to determine the responses of the activated 
sludge culture to antibiotic substances by means of modelling tools which enables to 
determine the kinetic and stochiometric constants of the mixed culture. 
By comparing real and calculated values, it‘s been aimed to propose better 
operational modes for more efficient treatment.  
For this purpose, the pharmaceutical plant in Turkey was selected which produces 
drugs in many forms and antibiotics. With its 763 personnel and 8 different 
production line, the plant generates 95.000 m³ wastewater in one  year.  
The plant has biological treatment and chemical treatment systems. Chemical 
treatment is only used when SS value decreases below 1500 ppm. Wastewater COD , 
SS, pH values are measured daily for influent and effluent of treatment system. It is 
aimed to meet the Water Pollution Control Regulation criteria for pharmaceutical 
xxii 
 
industry. System has  COD treatment efficiency  around %90 which was shown also 
by conventional characterization experiments 
Conventional characterization ,respiromeric analysis were conducted on the sampled 
wastewaters. Also Particle Size Distribution Analysis (PSD) was done via Sequential 
Filtration/Ultrafiltration analysis.Modelling study was also conducted using Aquasim 
program , ASM1 model.Stochiometric and kinetic coefficients were found and 
compared to literatural values.Ks and Mh values were found typical for 
pharmaceutical industry wastewaters. 
Results of these tests show that COD removal efficiency of treatment meets the 
criteria of Water Pollution Control Regulation for dicharge limits of COD and pH. It 
is concluded that aerobic biological treatment is effective and sufficient for the 
wastewater generation of the plant.  
The results of the model calibration related to the assessment of kinetic and 
stoichiometric coefficients reveals the biodegradable nature of the pharmaceutical 
wastewater. 
From PSD analysis results it is seen that biological treatment was in removing all 
size ranges except soluble  inert COD fraction.  
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İLAÇ ENDÜSTRİSİ ATIKSULARINDA AKTİF ÇAMUR PROSESİNİN 
KARAKTERİZASYON VE MODELLEMESİ 
ÖZET 
İlaçların dünya üzerindeki genel dağılımları ,günümüzün en önemli çevre 
problemlerinden biri olarak görülmektedir.Tıbbi olarak ilaç, insan ve hayvanlarda 
hastalıklardan korunma ve tedavi etme amacı güden, yardımcı maddeler ile 
zenginleştirilerek kullanıma sunulan dozaj şekli olarak tanımlanmaktadır. İlaçlardan 
kalan atıkların idrar, dışkı yoluyla veya duş sırasında suya karışması , canlı 
organizmalarla etkileşimde bulunmak üzere tasarlanan bu maddelerin, sudaki 
canlıları kısa sürede etkilemesine, bunun da ekosistem ve insanlar için potansiyel 
tehlike oluşturmasına yol açmaktadır. 
Düşük düzeyde bile olsa bu tür bileşikler, su canlıları üzerinde teşhis edilemeyen, 
yavaş biriken etkilere neden olabilir hatta yeni su canlılarının ortaya çıkmasına yol 
açabilir. Diğer taraftan bu tür kirleticiler bakterilerde direnç gelişimine neden 
olabilmektedir. Yüzey ve yer altı sularının artan şekilde kimyasal maddelerle 
kirlenmesinin, sudaki yaşam ve insan üzerinde uzun vadeli ve tehlikeli sonuçlar 
doğurması beklenmektedir.Her yıl yaklaşık 300 milyon ton endüstriyel ve tüketiciler 
tarafından kullanılan yapay bileşiklerin atıkları, tarımsal olarak kullanılan 140 
milyon ton gübre ve bir kaç milyon ton tarımsal ilaç ve kazayla 0,4 milyon ton petrol 
ve petrol ürünlerinin doğal sulara karışmakta olduğu düşünüldüğünde öngörülen 
zararlar daha da ön plana çıkmaktadır. Ürkütücü olabilecek potansiyel etkilerinden 
dolayı gittikçe popüler hale gelen bu konuda dünya çapında toplum baskısı 
artmaktadır.Bu nedenle yakın gelecekte birçok ilaç için mevzuatların sıkılaştırılması 
ve buna bağlı olarak arıtma tesislerinin uymak zorunda olduğu deşarj standartlarının 
da çok daha sıkı olması beklenmektedir. 
Dünyada ve ülkemizde en çok tüketilen ilaç gruplarının başında antibiyotikler 
gelmektedir.Yunanca anti (karşı) ve bios (yaşam) sözcüklerinden türetilen antibiyotik 
sözcüğü; küf mantarlarında bulunan ya da yapay olarak üretilen , bakteri ve diğer 
mikroorganizmaların gelişimini durduran ya da onları yok eden maddelerin ortak adı 
olarak tanımlanmaktadır.Antibiyotikler, etki derecelerine, etki mekanizmalarına, 
kimyasal yapılarına ve farmakinetik özelliklerine göre çeşitli şekillerde 
sınıflandırılabilir.Avrupa birliği ülkelerinde insan ve veteriner ilaç yapımında 
yaklaşık 4000 farklı etken madde kullanılmaktadır.Bu maddelerin çevreye karşı olan 
olası etkileri yeterince değerlendirilmemiştir. 
Antibiyotiklerin çevresel ortamda canlılar üzerindeki etkileri akut ve kronik etkiler 
olarak iki farklı alanda değerlendirilebilir.Akut etki, antibiyotiklerin tek bir doz 
uygulanması sonucunda ve genellikle kısa bir süre içinde meydana getirdiği zarar 
olarak ifade edilir.Kronik etki ise, uzun süre boyunca canlıların bu kimyasal 
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maddelere maruz bırakılması ile belirlenir.Zamanın belirli periyotlarında tekrar 
tekrar kullanılan küçük dozlardan ortaya çıkan küçük dozlardan ortaya çıkan her 
türlü zararlı kronik etki olarak ifade edilir.Bazı antibiyotiklerin akut toksisite etkileri 
hakkında yapılan çalışmalarda çeşitli tedavi gruplarından farklı ilaçların toksisite 
verileri elde edilmiştir.Yapılan akut toksisite deneylerinde, sucul mikroorganizmalara 
akut etki yapan konsantrasyonların , ilaç kalıntılarından dolayı çevresel ortamlarda 
bulunan konsantrayonlardan 100-1000 kat daha yüksek olduğu görülmüştür.Bu 
nedenle ilaçların doğrudan sucul ortamlara dökülmesi durumunda, sucul canlılara 
akut toksisite tehtidi oluşturacğı ifade edilmektedir.Bunun yanı sıra, birçok sucul 
ortamda yaşayan canlı türleri uzun süreli veya tüm yaşamı boyunca antibiyotik gibi 
mikrokirleticilerin ekişinde kalmış da olabilir. Bu nedenle bu mikrokirleticilerin 
kronik potasiyel etkilerinin değerlendirilmesi önem taşımaktadır.Ancak 
antibiyotiklerin kronik etkileri hakkında çok az veri bulunmakta, kronik etkileri de 
genellikle bilinmemektedir. Bu konuda çok daha fazla spesifik çalışmaların 
yapılması gerekmektedir.  
İlaç endüstrisi formulasyon altkategorisi atıksuları, farmasötik aktif bileşikler 
üretildikten sonra kullanıcıya sunulmak üzere uygun dozajlarda tablet, kapsül, sıvı 
veya merhem şeklinde formüle edilmesi işlemlerinden meydana gelmektedir.Bu 
nedenle formulasyon altkategorisinden oluşan atıksuların ürüne bağlı olarak 
kaynaklarının, miktarlarının ve karakterinin belirlenmesi önem taşımaktadır.Bu 
çalışmada ilaç endüstrisi formulasyon altkategorisinde kaynak bazında , Lak Tablet, 
Tablet, Likit ve Antibiyotik üretimlerinden meydana gelen atıksuların ürün esas 
alınarak miktarlarının belirlenmesi, karaterizasyon çalışmasının yapılması ve bu 
atıksuların arıtılabilirliğinin incelenmesi hedeflenmiştir. 
Bu çerçevede Türkiye‘de formulasyon kategorisinde üretim yapan bir ilaç üretim 
tesisi çalışma konusu olarak seçilmiştir. Türkiye‘nin pazar payı ve üretim adedi 
olarak önde gelen firmalarından olan bu firmada katı formda tablet, kapsül, toz ve 
granül olarak, sıvı formda ampul ve flakonlar, şurup, süspansiyon ve spreyler, pomat 
formunda merhemler, suporizituvar ve jeller , antibiyotik çeşidi olarak da beta laktam 
antibiyotiklerden penisilin ve sefalosporinler çeşitli formlarda üretilmektedir. 
Tesisin üretim prosesleri incelenmiştir.Yıl boyunca oluşan atıksular kaynakları ve 
miktarları ile ölçümlenmektedir. Tesiste 763 kişi üretimve bakım bölümleri 3 
vardiyalı düzende olmak üzere çalışmaktadır. Oluşan atıksular evsel ve endüstriyel 
kaynaklı olmak üzere iki farklı karakterde olmakla birlikte arıtma tesisine beraber 
veilmektedir. Tesiste biyolojik arıtma sistemi mevcuttur. Ön arıtma olarak kimyasal 
arıtma sistemi mevcut olmakla birlikte askıda katı madde oranı 1500 ppm‘nin altına 
düştüğünde devreye alınmaktadır.Biyolojik arıtma için 2 adet silindirik 675 m³ 
hacimli reaktör kullanılmaktadır.Biyolojik arıtma; dolum, reaksiyon, çökme ve çıkış 
akımının çekilmesi evrelerinden oluşmaktadır. 
Atıksu sistemine giren ve çıkan suyun hacim, KOI, BOI, pH değerleri günlük olarak 
ölçülmekte ve sistemin atıksu deşarj limitlerini (SKKY baz alınarak) sağladığı 
kontrol edilmektedir. Sistemin KOI bazında arıtım verimi ölçümleri %90‘ın üzerinde 
seyretmektedir.  
Çalışmada atıksu arıtma verimleri deneysel olarak ölçümlenmiştir. Atıksu arıtma 
sistemine giren ve çıkan sudan 2 farklı mevsimde alınan numunelerde yapılan 
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respirometrik ölçümlerde sağlanan değerlerin tesis ölçümleri ile uyumlu olduğu 
görülmüştür. 
Repirometrik deneyler sonucunda elde edilen oksijen tüketim hızı verileri, Aquasim 
olarak adlandırılan bir bilgisayar programı aracılığı ile ASM1 modeline uygun olarak 
modellenmiştir. 
Model kullanılmasının amacı,ilgili stokiyometrik ve kinetik katsayılarınn 
belirlenmesidir. Belirlenen katsayılar daha sonra literatürde benzer proseslere ait 
verilerle kıyaslanmıştır. Bu kıyaslama neticesinde sonuçalrın literatür verileri ile 
uyumlu olduğu görülmüştür. 
Son zamanlarda partikül boyut dağılımı bazlı KOİ bileşen analizi endüstriyel 
atıksuların alternatif karakterizasyon çalışması olarak başarı ile kullanılmaktadır.Bu 
analiz KOİ bileşenlerinin partiküler anlamda boyutlarının biyolojik bozunma 
karakterlerine bağlantılı olduğunu göstermektedir. Partikül Boyut Dağılım analizi 
Sıralı filtrasyon/Ultrafiltrasyon metodu  ile gerçekleştirilmiştir. PBD bazlı COD 
dağılımları giriş ve çıkış akımları için yapılmış, bu şekilde arıtma metodunun hangi 
boyutlarda ne ölçüde gerçekleştiği görülmüştür. İncelenen tesiste partiküler, 
kolloidal, suprakolloidal boyutlarda etkili bir arıtma verimi gözlemlenmekle birlikte 
çözünmüş fraksiyonda aynı verim görülmemiştir.Respirometrik ölçümlerde bulunan 
inert KOI değerleri ile de görülen bu sonuç biyolojik arıtmanın verimi ile bağlantılı 
olmamakla birlikte inert fraksiyonun sistemden bozunmadan geçmesi ile ilişkili olup  
ayrıca ölen mikroorganizma kalıntıları ile de çoğalmaktadır. 
Respirometrik analiz ve Ardışık Filtrasyon / Ultrafiltrasyon analizleri ile de 
ölçümlendiği üzere MH ve Ks değerleri literatür verileri ile uyum göstermektedir. 
Biyoloji arıtma verimi sonuçları firmanın ölçümleri ile uyum göstermektedir. 
Aerobik biyolojik arıtma yöntemi tesisin atıksu karakteri için uygundur.Farklı 
proseslerden gelen atıksuların birleşerek arıtma sistemine verilmesinin antibiyotik 
türlerinin inhibisyon özelliğini dilüsyon yoluyla azalttığı, bu sayede ön arıtma sistemi 
olarak kullanılan kimyasal arıtmaya askıda katı madde oranı belli seviyenin altında 
olduğu için gerek görülmediği görülmüştür. Benzer sonuçlara deneysel olarak da 
ulaşılmıştır. 
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1.  INTRODUCTION 
Pharmaceutical Sector wastewaters have become a problem from the environmental 
point of view.The reason of it is non or limited biodegradability of  some of their 
ingredients. The presence of human pharmaceutical compounds in surface waters is 
an emerging issue in environmental science .While water purification techniques 
could potentially remove these pollutants from wastewater streams , the high cost 
involved suggests that more attention should be given to the potential for the 
optimization of current treatment processes, and reduction at source in order to 
reduce environmental contamination. 
Wastewater usually contain pharmaceuticals either as excretion products resulting 
from metabolism or as a consequence of the inaccurate disposal of unused or out of 
date drugs.In wastewater treatment plants (WWTP); a pharmaceutical compound and 
its metabolites may undergo a partial or complete mineralization, a slow 
biodegradation after binding on solid sludge, or may pass unchanged  through the 
wastewater treatment plant.Toxic effects must also being investigated. Many drugs 
are not fully metabolized in the body and so may be excreted to the sewer system. 
Numerous pharmaceutical compounds have been shown to pass through sewage 
treament plants (STPs) and contaminate the aquatic environment. 
1.1 Purpose of Thesis 
In this study, the wastewaters of the pharmaceutical plant in Turkey which has a 
biological treatment system had been investigated. It is  aimed to determine the 
responses of the activated sludge culture to antibiotic substances by means of 
modelling tools which enables to determine the kinetic and stochiometric constants 
of the mixed culture.Therefore, relevant kinetic and stochiometric coefficients were 
achieved using ASM1 pattern in the study. 
By comparing real and calculated values, it‘s been aimed to propose better 
operational modes for more efficient treatment.  
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1.2.Scope of Thesis 
In the thesis, the following steps will be conducted: 
 Conventional characterization of the investigated firm wastewaters. 
 Respirometric analysis on the the investigated firm wastewaters. 
 Particle Size Distribution analysis of the investigated plant wastewater by 
Ultrafiltration Method 
 Modelling of the results 
 Overall evaluation 
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2. LITERATURE REVIEW 
2.1.Pharmaceutical Industry 
The term ‗pharmaceutical‘ covers a wide-ranging class of compounds with 
substantial variability of structures, function, behaviour and the activity. Developed 
to elicit a biological effect , they are used in both humans and animals to cure 
disease, fight infection, and/or reduce symptoms. Approximately 3000 different 
pharmaceutical compounds including painkillers , antibiotics, antidiabetics, beta 
blockers, contraceptives, lipid regulators, antidepressants, impotence drugs and 
cytostatic agents are used in Europe (Ternes et al, 2006). Globally production and 
consumption of these compounds are considered around 100.000 ton/year 
(Kummerer 2004).Parallel to the increase in the extensive usage of antibiotics, it is 
unavoidable that these chemicals are released into the environment.Therefore, the 
adverse effect on the environment and health brought from the processing and 
disposal of these products became important issue in the field of environmental 
engineering.Antibiotics generally remain in the effluent of wastewater treatment 
plants due to difficult treatability with conventional treatment systems.They also 
spoil ecological balance to form toxicity to organisms in ecosystem and biological 
treatment systems. 
2.1.1.Types of Pharmaceutical Processes and Products  
The activities of the pharmaceutical industry can be classified into three main 
categories: 
2.1.1.1.Research and development 
2.1.1.2.Primary manufacturing to produce the bulk drugs 
        - Chemical Synthesis 
        - Fermentation 
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        - Biological and Natural Extraction 
2.1.1.3.Secondary manufacturing (mixing, compounding or formulating) 
2.1.1.1. Research and Development 
This subcategory contains the microbiological and pharmalogical research studies 
that are done for production of a new drug (Duman, 2006;Sert 2006).Common 
wastes are halogenated solvents, non-halogenated solvents, organic chemicals, 
organic chemicals, natural products, biomass, radionuclides,oxidizers, acids, bases, 
and myriad of reagents.The quantities are significant in comparison to those from 
manufacturing operations. 
2.1.1.2.Primary manufacturing to produce the bulk drugs 
     - Chemical synthesis 
Mostly drugs are produced by chemical synthesis.The process involves sequencing 
batch reactors.These reactors are used for solvent extraction and crystallization, 
mixing of solvents, boiling and cooling.Chemical synthesis wastewaters have 
complex structures and hard to treat. 
Primary sources of wastewater from chemical synthesis operations are:  
a. Process wastes such as spent solvents, filtrates, and concentrates;  
b. Floor and equipment wash water;  
c. Pump seal water;  
d. Wet scrubber wastewater;  
f. Spills.  
Wastewater from chemical synthesis plants can be characterized as having high 
BOD, COD, and TSS concentrations; large flows; and extremely variable pH values, 
ranging from 1.0 to 11.0.Wastes can show inhibitory affect on biological treatment 
systems. (Duman, 2006;Sert, 2006) 
        -Fermentation 
Most antibiotics and steroids are produced by the fermentation process, which 
involves three basic steps: inoculum  and seed preparation, fermentation, and product 
recovery. Wastewater mostly come from fermentation and product recovery. For 
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fermentation process; acetone, methanol, isopropyl alcohol, etil alcohol and amil 
alcohol is used. Primery pollutants are methlene chloride, toluen and phenol. These 
wastewaters have high BOD, COD and SS. 
The  wastewater sources for fermentation process are given below  
a.Surface and equipment cleaning waters 
b.Used solvents coming from extraction process 
c.Cooling waters 
Sterilization of equipments used in fermentation process are mostly done by steam 
and phenol sometimes.Chemical disinfectants seriously increases pollution level.  
(Duman, 2006;Sert, 2006). 
-Biological and natural extraction 
Extraction is an expensive manufacturing process which requires collecting and 
processing large volumes of specialized plant or animal matter to produce small 
quantities of products.  
The main  sources of wastewater from biological/natural extraction operations are: 
 a. Spent raw materials (plan tor animal tissue) 
 b. Floor and equipment wash water; 
 c. Chemical wastes coming from purification and extraction processes (methilen 
chloride, toluen,  chloroform, methanol, acetone, isopropanol) 
 d. Cleanup of spills. 
Wastewater from extraction plants is generally characterized by low BOD , COD, 
and TSS concentrations; small flows; and pH values of approximately 6.0 to 8.0. 
(Duman, 2006;Sert, 2006) 
2.1.1.3.Secondary manufacturing (mixing, compounding or formulating) 
Pharmaceutically active ingredients are generally produced by batch processes in 
bulk form and must be converted to dosage form for consumer use. Common dosage 
forms for the consumer market are tablets, capsules, liquids, and ointments. In 
addition, active ingredients can also be incorporated into patches and time release 
capsules. 
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The primary objective of mixing, compounding, or formulating operations is to 
convert the manufactured products into a final, usable form. The necessary 
production steps typically have small wastewater flows because very few of the unit 
operations generate wastewater. The primary use of water is in the actual formulating 
process, where it is used for cooling and for equipment and floor washing. 
Wastewater sources from mixing, compounding, or formulating operations are:  
 a. Floor and equipment wash water, 
 b. Wet scrubbers, 
 c. Spills.  
An analysis of the pollutant information in the pharmaceutical manufacturing 
database shows that wastewater from mixing, compounding, or formulating plants 
normally has low BOD , COD, and TSS concentrations; relatively small flows; and 
pH values of 6.0 to 8.0. 
2.1.2. Pharmaceutical Manufacturing Process Variability  
The wastewater effluent flow and composition from a typical pharmaceutical 
manufacturing facility can be highly variable. Factors contributing to such variability 
are: 
 Campaigning 
 Batch processing 
 Wastewater commingling 
Because many pharmaceutical products are manufactured in campaigns, most 
wastewater is generated during product changeover. The process equipment must be 
cleaned out to avoid product contamination. The composition of the wastewater will 
vary according to the products that were manufactured on that process line. 
Pharmaceuticals are manufactured by batch and continuous manufacturing 
operations. Batch-type production is by far the most common manufacturing 
technique. Many pharmaceutical facilities conduct multiple batch operations, some in 
series and some concurrently. Often several of the required batch processes are 
performed at the same time in separate reactors, each with its own schedule. Each 
batch may have unique waste stream characteristics. In fermentation operations, it 
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can take a few days to several weeks to complete the ferment, during which little or 
no wastewater is generated. However, during product recovery operations, high-
volume, high-strength wastewaters are generated. It is also common practice in the 
pharmaceutical manufacturing industry to commingle organic contaminated 
wastewaters. In many cases commingling is necessary to collect sufficient 
wastewater volume to properly operate an economically sized treatment unit such as 
a steam stripper. Commingled wastes may be added to the treatment unit feed tank 
on a variable schedule, thus altering the feed composition on a real-time basis. In 
other cases, segregating for purposes of recovery and treatment may be appropriate 
and cost effective. 
A variety of solvents are used in the pharmaceutical manufacturing industry and end 
up in the industry's wastewater. Many solvents are process-specific and cannot be 
interchanged in other pharmaceutical processes.  
2.1.3. Pharmaceutical Dosage Forms 
A dosage form is a combination of drug substances and excipients to facilitate 
dosing, administration, and delivery of the medicine to the patient. The design and 
testing of all dosage forms target drug product quality. 
2.1.3.1. Aerosols 
Aerosols are preparations packaged under pressure and contain therapeutic agent(s) 
and a propellant that are released upon activation of an appropriate valve system.The 
aerosol dosage form refers only to those products packaged under pressure that 
release a fine mist of particles or droplets when activated.  
Aerosol preparations may consist of either a two-phase (gas and liquid) or a three-
phase (gas, liquid, and solid or liquid) formulation.  
2.1.3.2. Capsules 
Capsules are solid dosage forms in which the Active Pharmaceutical Ingredients 
(API) and excipients are enclosed within a soluble container or shell. The shells may 
be composed of two pieces, a body and a cap, or they may be composed of a single 
piece.Two-piece capsules are commonly referred to as hardshell capsules, and one-
piece capsules are often referred to as soft-shell capsules. 
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2.1.3.3. Dry powder ınhalers 
The dry powder inhaler (DPI) consists of a mixture of drug(s) and carrier, and all 
components exist in a finely divided solid state packaged as a unit dose. The dose is 
released from the packaging by an appropriate mechanism and is mobilized into a 
fine mist only upon oral inhalation by the patient. 
2.1.3.4. Creams 
Creams may be formulated from a variety of oils, both mineral and vegetable, and 
from fatty alcohols,fatty acids, and fatty esters. The solid excipients are melted at the 
time of preparation. Emulsifying agents include nonionic surfactants, detergents, and 
soaps. Soaps are usually formed from a fatty acid in the oil phase hydrolyzed by a 
base dissolved in the aqueous phase in situ during the preparation of creams. 
2.1.3.5. Lotions 
Lotions usually are prepared by dissolving or dispersing the API into the more 
appropriate phase (oil or water), adding the appropriate emulsifying or suspending 
agents, and mixing the oil and water phases to form a uniform fluid emulsion. 
2.1.3.6.  Foams 
Medicated foams are emulsions containing a dispersed phase of gas bubbles in a 
liquid continuous phase containing the API. Medicated foams are packaged in 
pressurized containers or special dispensing devices and are intended for application 
to the skin or mucous membranes. 
The medicated foam is formed at the time of application. 
Medicated foams intended to treat severely injured skin or open wounds must be 
sterile. 
2.1.3.7. Medical gases (ınhalation materials) 
Medical gases are products that are administered directly as a gas. A medical gas has 
a direct pharmacological action or acts as a diluent for another medical gas. 
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2.1.3.8.Gels 
Gels (sometimes called jellies) are semisolid systems consisting either of suspensions 
of small inorganic particles or of organic molecules interpenetrated by a liquid. 
2.1.3.9. Granules 
Granules are solid dosage forms that are composed of agglomerations of smaller 
particles. Granules often are the precursors used in tablet compression or capsule 
filling. Although this application represents a pharmaceutical intermediate and not a 
final dosage form, numerous commercial products are based on granules. 
2.1.3.10. Medicated gums 
Medicated gum is a semisolid confection that is designed to be chewed rather than 
swallowed. Medicated gums release the API(s) into the saliva. 
2.1.3.11. Implants 
Implants are long-acting dosage forms that provide continuous release of the API for 
periods of months to years. They are administered by the parenteral route.For 
systemic delivery they may be placed subcutaneously,or for local delivery they can 
be placed in a specific region in the body. 
2.1.3.12. Inserts 
Inserts are solid dosage forms that are inserted into a body cavity other than the 
rectum.The API is delivered in inserts for local or systemic action. 
2.1.3.13. Liquids 
As a dosage form a liquid consists of a pure chemical in its liquid state. Examples 
include mineral oil, isoflurane,and ether. 
2.1.3.14. Lozenges 
Lozenges are solid oral dosage forms that are designed to dissolve or disintegrate 
slowly in the mouth. They contain one or more APIs that are slowly liberated from 
the flavored and sweetened base. 
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2.1.3.15. Ointments 
Ointments are semisolid preparations intended for external application to the skin or 
mucous membranes.APIs delivered in ointments are intended for local action or for 
systemic absorption. 
2.1.3.16. Pastes 
Pastes are semisolid preparations of stiff consistency and contain a high percentage 
of finely dispersed solids. Pastes are intended for application to the skin, oral cavity 
or mucous membranes. 
2.1.3.17. Transdermal systems (patches) 
Transdermal drug delivery systems (TDSs) are discrete dosage forms that are 
designed to deliver the API(s)through intact skin to the systemic circulation. 
2.1.3.18. Pellets 
Pellets are dosage forms composed of small, solid particles of uniformshape 
sometimes called beads.Pellets may be administered by the oral (gastrointestinal) or 
by the injection route  
2.1.3.19. Pills 
Pills are API-containing small round solid bodies intended for oral administration. At 
one time pills were the most extensively used oral dosage form, but they have been 
replaced by compressed tablets and capsules.Pills are distinguished from tablets 
because pills are manufactured by a wet massing and molding technique,while 
tablets are formed by compression. 
2.1.3.20.Powders 
Powders are defined as a solid or a mixture of solids in a finely divided state 
intended for internal or external use.Powders used as pharmaceutical dosage forms 
may contain one or more APIs and can be mixed with water for oral administration 
or injection. 
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2.1.3.21. Medicated soaps and shampoos 
Medicated soaps and shampoos are solid or liquid preparations intended for topical 
application to the skin or scalp followed by subsequent rinsing with water. 
2.1.3.22. Solutions 
A solution is a liquid preparation that contains one or more dissolved chemical 
substances in a suitable solvent or mixture of mutually miscible solvents. 
2.1.3.23. Sprays (nasal, pulmonary, or solutions for nebulization) 
A spray is a preparation that contains a therapeutic agent(s) in either the liquid or 
solid state and is intended for administration as a fine mist of small aqueous droplets. 
2.1.3.24. Suppositories 
Suppositories are dosage forms adapted for application into the rectum. They usually 
melt, soften, or dissolve at body temperature. 
2.1.3.25. Suspensions 
A suspension is a biphasic preparation consisting of solid particles dispersed 
throughout a liquid phase. 
2.1.3.26. Tablets 
Tablets are solid dosage forms in which the API is blended with excipients and 
compressed into the final dosage. Tablet presses use steel punches and dies to 
prepare compacted tablets by the application of high pressures to powder blends or 
granulations. 
2.1.3.27. Tapes 
A tape is a dosage form suitable for delivering APIs to the skin. It consists of an 
API(s) impregnated into a durable yet flexible woven fabric or extruded synthetic 
material that is coated with an adhesive agent. 
2.1.4. Turkish Pharmaceutical Sector 
Turkey has a developed pharmaceutical industry in terms of production standards, 
technology and capacity. The production facilities have been inspected continuously 
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by Ministry of Health, and accredited internationally by International Accreditation 
Authorities (IEIS, 2008).  
Today, there are approximately 300 pharmaceutical firms operating in Turkey, many 
of them just maintain a marketing organization. Among 42 manufacturing facilities 
in Turkey, 14 belong to multinational firms.  
Approximately 25.000 people are employed in the sector due to the sector report of  
2010, of which 50% have a university degree. (pharmacist 4, 5%, physicians 3%, 
chemical engineers 7, 5%, chemists 7%, biologists 9, 5%) (Petrol-İş Pharma.Sector 
Analysis) 
In 2007, pharmaceutical imports increased by 16% and reached 3.52 billion USD 
whereas the export increased by 14% and reached 357 million USD. The export-
import ratio in 2007 was 10.1% (after 10.3% in 2006). 
2.2. ANTIBIOTICS 
Compounds which are alien to existing enzyme systems are called xenobiotics.These 
compounds are generally synthetically produced and cover many groups of 
chemicals including persistant compounds (van der Meer et al, 1992). 
Pharmaceuticals are examples of such xenobiotic compounds which have the 
potential to accumulate in the food chain and threaten human health (van der Meer et 
al, 1992)The pharmaceuticals may contain antibiotics , antidepressants and many 
other chemicals. 
2.2.1. Classification of Antibiotics 
Antibiotics can be grouped by either their chemical structure or mechanisms of 
action.The most common method classifies them according to their chemical 
structure as antibiotics sharing the same or similar chemical structure will generally 
show similar patterns of antibacterial activity, effectiveness, toxicity and allergic 
potential (Ternes and Joss; Beers et al, 2003) 
Most commonly used types of antibiotics are Aminoglycosides, Penicillins, 
Fluoroquinolones, Cephalosporins, Macrolides and Tetracylines.Classification of 
antibiotics is shown on Figure 2.1. 
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Figure 2.1. Classification of Antibiotics. 
2.2.1.1.Penicillins 
Penicillins are produced from some kinds of fungi and have bactericidal effect.They 
can be produced synthetically or semi-synthetically. The basic structure in all of 
them is 6-aminopencillicacid (6-APA).They show their effect by inhibiting cell wall 
production.                                        
       Penicillin Fermentation 
 
 
                                                     Biosyntetic Penicillins         Natural Penicillins 
 
                                                                                         Penicillin G       Chemical-Enzymatic  
                                                                                                                      reaction  
                                                                                                                         to Penicillin G (6-APA) 
                                                                                                                                
                                                                                                                
                                                                                                                          Semisyntetic Penicillin  
                                                                                                                      (Amoxycillin)  
                                          
                                        Figure 2.2.  Classification of Penicillins. 
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Figure 2.3.  General Chemical Structure of Penicillins. 
2.2.1.2. Cephalosporins 
They‘ve been produced first in 1940‘s from the fungi Cephalosporicum acremonium. 
They‘re wide spectrum beta lactam antibiotics. They have the same effect 
mechanism as other penicillins.They inhibit cell wall synthesis of bacteria.They are 
classified by their different properties and molecular structures. 
1. Generation cephalosporins are active mostly on aerobic Gr (+) Coccies. 
2. Generation cephalosporins are active mostly on selected Gr (-) microorganisms 
3. Generation cephalosporins are active mostly on  Gr (-) microorganisms 
4. Generation cephalosporins have the widest range of effect. 
 ( Şensoy, 2011) 
 
Figure 2.4. General Structure for Cephalosporins. 
(Nemutlu and Kır, 2009) 
2.2.2.Degradation of b-Lactam Antibiotics 
The instability of b-lactam antibiotics in solution was observed to be a major hurdle 
in the development of penicillin and other useful b-lactam antibiotics. Therefore, 
degradation or stability study of b-lactam antibiotics has been of paramount 
importance not only for their market availability, but also to evaluate their 
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pharmacokinetic properties and adverse reactions. It is also interesting to note that 
stability or rate of degradation of different members of b-lactam antibiotics in vivo as 
well as in vitro has been quite different. However, the major pathways of their 
degradation have remained similar, leading to various breakdown products in a 
majority of the b-lactams.( A. D. Deshpande et al, 2004) 
2.2.2.1.Degradation of Penicillin 
Penicillin is a unique molecule containing unstable, highly strained and reactive b-
lactam amide bond. The degradation of penicillin takes place in various conditions, 
viz.alkaline or acidic, in the presence of enzyme b-lactamase or treatment of weak 
nucleophiles like water and metal ions. 
 
Figure 2.5. Pathways of degradation of penicillin in acidic and alkaline conditions. 
2.2.2.2. Degradation of Cephalosporins 
Although cephalosporins are more stable to hydrolytic degradation reactions than 
penicillins, they experience a variety of chemical and enzymatic transformations, 
whose specific nature depends on the side chain at C-7 and the substituenton C-3 
atom. 
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Figure2.6. Possible pathways of degradation of cephalosporin C. 
2.2.3. Antibiotic Resistance Mechanisms 
Resistance is decrease/loss of sensitivity to a certain antibiotic.Frequent and 
uncontrolled usage of antibiotics may cause this situation.Resistance to an antibiotic 
can be classified into 2 classes; natural resistance and achieved resistance (Yüce, A., 
2001) 
2.2.3.1. Natural resistance 
The root cause is microorganisms are in inactive state metabolically or they don‘t 
have a target structure for the effect mechanism of that antibiotic. 
2.2.3.2. Achieved resistance 
         -    Achieved resistance by mutation 
This effect is generally not the result of drug-microorganism contact, and there is no 
cause-effect relationship. Mutation occurs spontanously , there are lots of studies that 
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shows the mutation levels are almost the same in groups that are contact/not in 
contact with antibiotics.If resistance is chromosomal, this mutation may have been 
gained in one or more than one step. 
- One step mutation 
There is sudden occurance of resistance to the certain antibiotic after one or more 
contact. Enterobacter, Serretia , indol positive Proteus, Pseudomonas  aeroginosa 
and in some other species may gain one step resitance. Mutation cause them to 
increase β-lactamase that break down Sephalosporins. 
- Mutual step mutation  
Resistance occur slowly and in increasing mode.This type of resistance is called also 
as penillin type resistance.For the occurance of this type of resistance there must be  
sequential mutations in different parts of DNA. This type of resistance may occur 
against Penicillins and Tetracycllins. 
- Achieved resistance due to transfer of resistance gene 
Plasmids are cirsular shaped double helix DNA molecules. They are 
extrachromozomal genetic elements.Their molecular weight changes from 1-200 
billion daltons.More than one type of plasmids may take place in a cell. The plasmid 
is called a resistance (R) plasmid if they have resistance genes. 
Transpozons are special kind of DNA parts that are smaller and mobile, they take 
place in transfer of resistance.They can recombine themselves both to chromosomal 
DNA and to plasmids. 
The mechanisms of plasmids to transfer themselves from different environments into 
cells; 
- Transduction 
Bacteriophages (Bacterial viruses) transfer resistance plasmids.Upon entrance into 
bacterial cell, they take R plasmid into their viral protein cover. After division, 
bacteria with  copies of plasmids are formed, after than bacterial cell burst and 
hundreds of plasmids are scattered to environment.They make other bacteria resistant 
too. 
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- Conjugation:  
Resistant bacteria, together with sensitive bacteria form cytoplasmic bridge and one 
of R plasmids pass into sensitive cell , make it resistant too. 
- Transformation: 
R Plasmids and DNA parts in the environment due to the bacterial lysis, are taken by 
sensitive bacteria and make them resistant too. 
2.2.4. Emissions of Antibiotics to the Environment 
Antibiotics can enter the environment by a number of different pathways. Effluents 
of sewage treatment plant and pharmaceutical industry, waste from confined animal 
feeding operations and manure can be a source for antibiotic pollution  (Kuımar et 
al.2005) 
 
Figure 2.7. Principal routes of antibiotics in the environment. 
From the late 1980s, occurrence of human derived antibiotics in different 
environmental compartments has been reported. Later, it was found that animal 
feeding operations and aquaculture facilities are the other sources of antibiotics. 
Until now,numerous studies have been documented to report occurrence of human 
used antibiotics in environment and measured concentration was generally less than 
1 μg/L with few exception (Farre et al., 2001; Golet et al., 2002; Heberer, 2002; 
Miao and Koenig, 2002,Barreiro and Lores, 2003; McArdell et al., 2003; 
Stamatelatou et al., 2003; Vanderford et al., 2003; Cahill et al., 2004; Gobel et al., 
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2004; Gross et al., 2004; Kolpin et al., 2004;Wiegel et al., 2004; Glassmeyer et al., 
2005) 
However, significantly higher concentration of veterinary antibiotics up to 46 mg/kg 
(Martinez-Carbollo et al., 2007) has been detected in manure and thus manure 
amended soil contains high amount of antibiotics such as 100 μg/g in soil (Accinelli 
et al., 2007). Antibiotics are also detected in other natural sources such as 246 μg/kg 
in sediment (Lalumera et al., 2004); 20 μg/L in fauna (Pathak and Gobal, 2005); and 
1233 ng/g in plants (Migliore et al., 2003). 
Antibiotics which are released to aquatic environment may contaminate raw , treated, 
recycled, irrigation and recretion water.Bacterial resistance to antibiotics may be 
gained by bacteria.On the other hand, negative effects such as toxicity and inhibition 
may be observed on ecosystem bacteria (Rang et al, 1999)The global distribution of 
pharmaceuticals in the aquatic environment has become one of the main 
environmental problems in the last decade(Zuccato et al, 2005).Although, the 
environmental concentrations of pharmaceuticals are generally at trace levels (ng/L 
to low µg/L) in the environment, can be sufficient to induce toxic effects (Hernando 
et al, 2006)Persistence toward biodegradation and their biological activity are key 
properties of these pollutants, since they have been designed to cause DNA damage 
to bacteria or eukaryotic cells.They retain their chemical structure long enough to do 
their therapotic work and because of their continious input they could remain in the 
environment for a long time (Alexy et al,2004) Antibiotics are biologically very 
active ingredients by their interference property in enzymatic reactions.From 
environmental point of view, they violate the ecological balance by effecting water 
species like Daphnia magna by their toxic effect.(Lanzky and Halling-Sorensen, 
1997, Harrass et al, 1985, Macri et al, 1988). The inreasing usage of antibiotics in 
last 50 years have caused the genetical selection for many harmful bacteria.The 
genetic pool have changed dramatically.This irreversible effect have caused some 
type of bacteria to develop defense mechanism to this bactericidal effect. 
They spoil ecological balance to form toxicity to organisms in ecosystem and 
biological treatment systems. 
Toxic effects of common antibiotics on different organisms (bacteria, algae, Artemia 
saliva, Daphnia magna, etc.) have been found even at very low exposure doses 
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(Macri et al., 1988; Migliore et al., 1997;Wollenberger et al., 2000; Ferrari et al., 
2003)  
Abuse of antibiotics and the existence of residual antibiotics in the environment have 
been linked with the formation of antibiotic resistance (Boxall et al., 2003; Silver and 
Bostian, 1993).The occurrences of several kinds of antibiotics like macrolides and 
sulfonamides have been reported in many environmental samples such as municipal 
wastewater (McArdell et al., 2003), surface water, groundwater (Batt and Aga, 
2005),sludge and sediments (Lindberg et al., 2005). 
Elimination of pharmaceuticals in wastewater treatment plants is depended on many 
parameters like the sludge age, hydraulic retention time, temperature,pH, biomass 
concentration, polarity and biodegradability of the substance (Press and Kristensen, 
2007)  
2.3. The Treatability and the Toxicity of the Pharmaceutical Wastewater 
The solvents and antibiotics, pain drugs and some raw materials used in the 
pharmaceutical industry have shown to cause toxicity in wastewaters. Since 
antibiotics are resistant to biological treatment, the discharge to environment without 
treatment, causes high toxic effect. The effect of toxic material to treatment system 
changes according to types of microorganisms, type and concentration of toxic 
material, sludge age, biomass concentration, time of exposure and temperature. 
All microorganisms show different  reaction to toxic materials.The effect of toxic 
material depends on the toxic material/biomass percentage in the treatment 
system.The smaller is this amount, the lower is the effect on the microorganisms.To 
lower the effect of toxic material, wastewater must be given  to the sytem with 
dilution with domestic wastewater .The shortage of time of exposure of biomass 
results in smaller effect and biomass can return to its actual state but at the same time 
it may result with untreated toxic material. Therefore the care must be given on the 
below conditions; (Gülmez, 1997) 
 Enough time must be given for the biomass adapt to toxic material 
 To lower the toxic material amount with dilution with domestic wastewater to 
a level that biomass can compensate 
 The wastewater containing toxic material must be given to treatment system 
gradually 
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 The loss of biomass during acclimation must be minimized. 
The effect of antibiotics that are given to treatment systems after usage are not 
known widely. Kummerer et al, (2000) have investigated toxic effects of 3 different 
raw materials; Metronidazol, Ciprofloxacin and Ofloxacin. Metronidazol show low 
toxic effect to algs and  Daphnia . Ciprofloxacin is effective on the aerobic Gr(-) and 
Gr(+) bacteria. Ofloxacin show lower effect than Ciprofloxacin to Gr(-) bacteria.It‘s 
been showed that the antibiotics cannot be treated biologically in Closed Bottle Test 
(CBT) 
2.3.1. Pharmaceutical Industry Wastewater Treatment Options   
Different treatment techniques are applied to pharmaceutical wastewaters according 
to process profiles since they generally occur in sequencing batch reactors and 
pollution concentration differ in time.The main treatment techniques applied these 
wastewaters are: 
2.3.1.1.Biological treatment 
Biological treatment methods are used for treatment of pharmaceutical wastewater 
(Suman Raj and Anjaneyulu, 2005). They may be subdivided into aerobic and 
anaerobic processes. 
Aerobic applications include; 
 activated sludge  
 membrane batch reactors  
 sequence batch reactors  
(LaPara et al., 2002; Suman Raj and Anjaneyulu, 2005; Noble, 2006; Chang et al., 
2008 and Chen et al., 2008).  
Anaerobic methods include; 
 anaerobic sludge reactors,  
 anaerobic film reactors  
 anaerobic filters 
 (Gangagni et al., 2005; Enright et al.2005; Chelliapan et al., 2006; Oktem et al., 
2007;Sreekanth et al., 2009).  
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The wastewater characteristics play a key role in the selection of biological 
treatments.Solvents, APIs, intermediates and raw materials represent biologically 
recalcitrant substances which affect the efficiency of biological treatment systems 
(Oz et al., 2004; Helmig et al., 2007). Activated sludge (AS) treatment is unsuitable 
for the treatment of wastewater where the COD levels are greater than 4000 mg/L 
(Suman Raj and Anjaneyulu, 2005). 
Conventional activated sludge with a long hydraulic retention time (HRT) has 
historically been the method of choice for the treatment of pharmaceutical industry 
wastewater (El Gohary and Abou-Elea, 1995; Oz et al., 2004). It has a lower capital 
cost than more advanced treatment methods and a limited operational requirement; it 
is generally more environmentally friendly than chlorination. However,high energy 
consumption, the production of large amounts of sludge (Sreekanth et al., 2009) and 
operational problems including colour, foaming and bulking in secondary clarifiers 
are associated with activated sludge plants (Oz et al., 2004). Factors which affect the 
efficiency of activated sludge facilities for the treatment of pharmaceutical 
wastewater include HRT, temperature, pH, dissolved oxygen (DO), organic load, 
microbial community,presence of toxic or recalcitrant substances and the batch 
operation of pharmaceutical production facilities (LaPara et al., 2001a; LaPara et al., 
2002; Suman Raj and Anjaneyulu, 2005). These variables require modification for 
adaptation to pharmaceutical industry wastewater. 
The impact of pharmaceuticals on the AS process appears to be negligible under 
normal operating conditions (Stamatelatou et al., 2003). However at higher 
concentrations, which may be expected in the wastewater of pharmaceutical 
manufacturing facilities,they may become inhibitory. While there are a number of 
limited studies on the removal efficiency of APIs from pharmaceutical 
manufacturing facilities, it is known that removal efficiency of municipal facilities is 
dependent on the APIs present in the wastewater (Urase et al., 2005). AS is an 
efficient method for the removal of some APIs, but not all from municipal facilities 
(Zwiener and Frimmel, 2003; Castiglioni et al., 2006; Watkinson et al., 2007). β-
Lactam and quinlone drugs in particular appear to be susceptible to aerobic 
oxidation. In a WWTP in Brisbane Australia,β-Lactam antibiotics showed high 
biodegradability due to hydrolic cleavage of the β-lactam ring. Lincomycin and 
sulphonamides were the least affected by AS treatment (Joss et al., 2005). Similar 
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studies have also found that the efficiency of the process is dependent on the 
compound under investigation (Joss et al., 2005). Ibuprofen, naproxen, bezafibrate 
and estrogens (estrone, estradiol and ethinylestradiol) showed a high degree of 
removal while sulfamethoxazole, carbamezapine and diclofenac showed limited 
removal (Clara et al., 2005; Joss et al.,2005; Xu et al., 2008). Removal efficiencies 
are likely to decrease due to the development of more resistant APIs (Khetan and 
Collins, 2007). 
The advantages of anaerobic treatment over aerobic processes is its ability to deal 
with high strength wastewater, with lower energy inputs, sludge yield,nutrient 
requirements, operating cost, space requirement and improved biogas recovery. 
However, because a wide range of natural and xenobiotic organic chemicals in 
pharmaceutical wastewaters are recalcitrant and nonbiodegradable to the microbial 
mass within the conventional treatment system, anaerobic processes are not always 
effective in removing these substances. 
2.3.1.2. Advanced treatment methods 
Alaton & Dogruel (2004) investigated a variety of advanced oxidation processes 
(AOPs; O3/OH-, H2O2/UV, Fe2+/H2O2, Fe3+/H2O2, Fe2+/H2O2/UV andFe3+/H2O2/UV) 
for the oxidative pre-treatment of real penicillin formulation effluent.The average 
COD0, TOC0, BOD5,0 were 1395, 920 and 0 mg/l. The selected wastewater 
corresponded to approximately 24% of the total daily effluent (=150m3/day) of 
which 47% was the process water. For the ozonation process the primary 
involvement of free radical species such as OH in the oxidative reaction could be 
demonstrated via inspection of ozone absorption rates. Alkaline ozonation and the 
photo-Fenton‘s reagents both appeared to be the most promising AOPs in terms of 
COD (49–66%) and TOC (42–52%) removal rates. It was demonstrated that the 
penicillin active substance can be completely removed at the selected experimental 
conditions accompanied by effective oxidation (i.e. 51-58% TOC and 72-81% COD 
removal). In separate treatability experiments conducted with aqueous amoxicillin 
solution.The ozonation of amoxicillin was studied by Andreozzi, Canterino, Marotta 
&Paxeus (2005). As for other pharmaceuticals, ozonation was proposed as a process 
for its abatement from Sewage Treatment Plant effluents. Chemical investigations 
showed that the ozonation process was characterized by low degree of mineralization 
24 
 
even for long treatment times. The results indicate that ozone attack was partially 
directed towards a reaction center different from the phenol ring or the protonated 
amino group, possibly towards the sulfur atom. No direct evidences of attack on 
sulfur atom with sulfoxide formation are found. Kinetic investigations allowed 
characterizing both the direct and radical mechanism of ozone attack to the 
molecule.It was found that the kinetic constant for the direct attack was strongly 
dependent upon the pH of the solutions. Hydrogen peroxide photolysis has been 
successfully adopted to evaluate the constant for OH radical attack to amoxicillin 
molecule at a pH 5.5.Boyd, Zhang & Grimm (2005) studied the chemical 
transformations of naproxen following chlorine oxidation, which was common in 
water and wastewater treatment systems. Synthetic waters containing elevated 
concentrations of naproxen were oxidized by free chlorine at naproxen:chlorine 
molar ratios of 0.02-3:1 and pH values of 5-9.The formation of naproxen products 
was dependent on pH, chlorine dosage and contact time. This study demonstrated 
that naproxen readily reacts with free chlorine and formed disinfection products. A 
bioreactor was fed with a naproxen solution and then fed with a solution at the same 
naproxen concentration following contact with free chlorine. Results indicated that 
naproxen was not degraded biologically. Dissimilarity, the naproxen solution 
containing products of chlorination could adversely affect the biofilm process, which 
potentially could impact the performance of biofilm. 
A membrane system including reverse osmosis (RO) and ultrafiltration (UF) was 
performed for the treatment of an oxytetracycline (OTC) waste liquor by Lie S., Lie 
X. & Wang (2004). The liquid samples contained a residual OTC of around 1000 
mg/l and a COD of about 10 000 mg/l. Using RO filtration with a volume reduction 
coefficient of 3.5, the organic content in its permeate was decreased from 10 000 mg 
COD/l to less than 200 mg COD/l, while OTC was reduced from more than 1000 
mg/l to lower than 80 mg/l. Oxytetracycline was concentrated more than 3 times to 
3000–4000 mg/l in the retentate. Due to likely the high concentration of large 
biopolymers interacting with OTC molecules, OTC could not be successfully 
recovered from the RO retentate by conventional crystallization. With additional 
treatment of ultrafiltration by 3K membranes, OTC crystallization and recovery from 
the RO retentate were significantly improved. A recovery ratio of more than 60% 
and a purity of higher than 80% were achieved. 
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Ternes & et al. (2003) investigated about a pilot plant for ozonation and 
UVdisinfection received effluent from a German municipal sewage treatment plant 
(STP) to test the removal of pharmaceuticals in iodinated X-ray contrast media 
(ICM) and musk fragrances from municipal wastewater. In the original STP effluent, 
5 antibiotics, 5 betablockers, 4 antiphlogistics, 2 lipid regulator metabolites, the 
antiepileptic drug carbamazepine, 4 ICM, the natural estrogen estrone and 2 musk 
fragrances were detected by LC-electrospray tandem MS and/or GC/MS/MS. 
ICM,derived from radiological examinations, were present with the highest 
concentrations. By applying 10–15 mg l−1 ozone (contact time: 18 min), all the 
pharmaceuticals investigated as well as musk fragrances and estrone were no longer 
detected. However, ICM (diatrizoate, iopamidol, iopromide and iomeprol) were still 
detected in appreciable concentrations. Even with a 15 mg l−1 ozone dose, the ionic 
diatrizoate only exhibited removal efficiencies of not higher than 14%, while the 
non-ionic ICM were removed to a degree of higher than 80%. Advanced oxidation 
processes (O3/UV-low pressure mercury arc, O3/H2O2), which were non-optimized 
for wastewater treatment, did not lead significantly to a higher removal efficiency for 
the ICM than ozone alone.The performance of the application of advanced oxidation 
processes to different industrial wastewaters-ozonation of pharmaceutical effluent 
was investigated by Balcıoglu et al. (2003). Depending upon the type of antibiotic 
60-72% COD and 30-96% aromatic amine (UV254) removals were achieved with an 
2592 mg/l h applied ozone dosage at a pH=7. The experiments were carried out in 
four different applied ozone doses in the range of 640-2960 mg/l h indicated that the 
fractional ozone utilization was more efficient at lower ozone concentrations. 
Increasing ozone döşe did not cause any change in BOD5/COD ratio.Balcıoglu & 
Otker (2003) studied the ozonation of three different synthetic pharmaceutical 
formulation wastewater containing two human antibiotics and a veterinary antibiotic 
to enhance the their biodegradability. The effects of pH and initial chemical oxygen 
demand (COD) value as well as addition of hydrogen peroxide on ozonation process 
were investigated. Ozonation experiments were performed in a 1500 ml capacity. 
Total organic carbon (TOC), COD, biochemical oxygen demand (BOD), and 
aromatic content (UV254) were the parameters followed to evaluate the performance 
of ozonation process. While BOD5/COD ratio of veterinary antibiotic formulation 
wastewater was increased from 0.077 to 0.38 with an applied ozone dosage of 2.96 
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g/l, the BOD5/ COD ratio for human antibiotic I and human antibiotic II was 
increased from 0 to 0.1 and 0.27 respectively. The results of this investigation 
showed that the ozonation process is capable of achieving high levels of COD and 
aromaticity removals at about their natural pH values. 
2.3.1.3. Chemical treatment methods 
A total of 23 coagulants/flocculants was tested, including salts, 
polyhidroxyaluminates,synthetic polymers as well as natural gums by Torres (1997). 
In a second stage, some mixing aspects were studied. The effects of the specific 
impeller,the agitation speed during the coagulation and flocculation stages, and the 
absence or presence of baffles was evaluated in a six-place agitation system. It was 
demonstrated that the appropriate coagulation-flocculation system was capable of 
diminishing the COD, the apparent color and the dissolved solids up to 40.6, 25.6 
and 39.4%, respectively. The best results were observed when using BL-5086, 
guargum, Niad II-3, Niad II-4 and locus beam gum. The impeller performance was 
highly dependent on the agitation speed for each fixed system. 
2.4. Respirometry and Activated Sludge Modeling 
2.4.1. COD fractionation in wastewater characterization 
COD fractination involves identification of inert and biodegradable COD together 
with readily biodegradable COD  slowly biodegradable fractions. 
The total organic matter,CT which is measured as COD is first classified in 2 groups 
depending on its biodegradability.Non-biodegradable organic matter is inert since it 
is not changed during wastewater treatment.Total inert COD, CI is the sum of the 
soluble, SI and particulate,XI forms of inert organic matter.SI passes through 
activated sludge system whereas XI retains and it can only be removed by sludge 
wastage. 
The biodegradable fraction of COD is divided into readily biodegradable, Ss and 
slowly biodegradable COD, Xs as they have quite different biodegradation 
rates.Simple carbohydrates, volatile fatty acids, alcohols constitute readily 
biodegradable fraction.Xs fraction includes soluble, colloidal, larger complex organic 
matter which cannot pass through the cell wall of the cell. For utilization of Xs, 
hydrolysis and conversion to simpler organic matter is required.Hydrolysis is 
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assumed to proceed slower compared to the utilization of readily biodegradable 
COD. The complex nature of wastewater indicates the need for the seperation of 
hydrolysable COD in two fractions:slowly hydrolysable COD, SH and readily 
hydrolysable COD, Xs.However, ASM1 model assumes single type of hydrolyzable 
COD. 
 
 
 
       
                              
       
 
 
Figure2.8. Distribution of COD fractions in wastewaters (Artan and Orhon, 1994). 
2.4.2. Respirometry  
Dissolved oxygen and nitrate are known to be final electron acceptors in carbon and 
nutrient removing treatment systems.Dissolved oxygen is used in establishing 
electron balance in aerobic balance in aerobic processes such as biodegradable COD, 
biomass and electron acceptor. Activated sludge models were developed which 
involve final electron acceptors such as dissolved oxygen and nitrate  (Orhon et al., 
2009).It defines oxygen uptake rate (OUR) showing the rate of oxygen utilization. 
Depletion of oxygen is monitored for a defined period of time. OUR is used for 
assessment of biodegradable COD fractions, wastewater characteristics, process 
kinetics and process control purposes in treatment systems (Ekama et al, 1986; 
Kappeler and Gujer,1992;Ubay Çokgör et al.,1998; Insel et al., 2003; Karahan et 
al.,2002; Sözen et al., 1998;Avcıoğlu et al.,1998;Sollfranf and Gujer, 1991) 
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2.4.3. Activated Sludge Modeling  
The identification of wastewater characteristics with regard to the organic content is 
useful both from the standpoint of process kinetics and prediction of effluent quality. 
Collective  analytical parameters such as biochemical oxygen demand (BOD) and 
chemical oxygen demand (COD), routinely used to reflect the total organics in 
wastewaters, do not correspond to the real system variable, i.e. the growth limiting 
substrate.COD is estimated to be a more useful parameter than BOD as it enables one 
to make appropriate correlations among substrate,biomass and dissolved oxygen in 
terms of electron equivalence. (Orhon and Çokgör ,1996) 
From a modelling standpoint, COD cannot differentiate between biodegradable and 
inert organic matter or between readily and slowly biodegradable fractions.The inert 
COD may be present in the influent or it may be generated during biological 
treatment as residual microbial products.This residual COD fraction is significant for 
industrial effluents and leads to misinterpretation of the biological treatability and 
kinetic analysis;the soluble inert COD fraction also becomes a challenging factor in 
meeting the effluent limitations expressed in terms of COD for a number of industrial 
categories. (Orhon and Çokgör ,1996). 
Modelling is a valuable tool for design of activated sludge systems,because it enables 
the role and impact of significant parameters to be analysed and so  helps to define 
and optimize the proposed process (Orhon and Çokgör ,1996) 
In 1983, the International Association on Water Quality (IAWQ, formerly IAWPRC) 
formed a task group, which was to promote development, and facilitate the 
application of, practical models for design and operation of biological wastewater 
treatment systems. The first goal was to review existing models and the second goal 
was to reach a consensus concerning the simplest mathematical model having the 
capability of realistically predicting the performance of single-sludge systems 
carrying out carbon oxidation, nitrification and denitrification. The final result was 
presented in 1987 as the IAWQ Activated Sludge Model No. 1(A Gen. Desc. of the 
IAWQ Activated Sludge Model No. 1 by Ulf Jeppsson, MSc, PhDDept of Industrial 
Electrical Engineering and Automation Lund Institute of Technology Lund, Sweden) 
Activated sludge models are generally based on IAWQ Activated Sludge Model 
No.1, ASM1 (Henze, 1987).Although it was designed for domestic or municipal 
29 
 
wastewater, for industrial applications the model should be carefully calibrated.It 
involve carbon removal, nitrification and denitrification processes.ASM1 generally 
takes into consideration 3 components:biomass, substrate and oxygen. The basic 
components and process of ASM1 for carbon oxidation is shown in Table 2.1. 
Table.2.1. Processes for carbon oxidation described in ASM1 (Henze et al, 1987). 
 
   2.4.3.1.Processes in ASM1 
Basically there are four different main processes defined in ASM1 (Henze et al., 
1987): 
 Growth of biomass 
 Decay of biomass 
 Ammonification of organic nitrogen 
 Hydrolysis of particulate organic matter 
The substrate flows in ASM1 are illustrated in Fig. 2.9. 
2.4.4. COD components in ASM1  
COD is selected as the most suitable parameter for defining the carbon substrates as 
it provides a link between electron equivalents in the organic substrate, the biomass 
and oxygen utilised. In ASM1 the COD is subdivided based on (1) solubility, (2) 
biodegradability (3) biodegradation rate and (4) viability (biomass): 
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Figure 2.9. The substrate flows in ASM1. 
• The total COD is divided into soluble (S) and particulate (X) components. 
• The COD is further subdivided into non-biodegradable organic matter and 
biodegradable matter. The non-biodegradable matter is biologically inert and passes 
through an activated sludge system in unchanged form. The inert soluble organic 
matter (SI) leaves the system at the same concentration as it enters. Inert suspended 
organic matter in the wastewater influent (XI) or produced via decay (XP) becomes 
enmeshed in the activated sludge and is removed from the system via the sludge 
wastage. 
• The biodegradable matter is divided into soluble readily biodegradable (SS) and 
slowly biodegradable (XS) substrate. Already here it should be stressed that some 
slowly biodegradable matter may actually be soluble. The readily biodegradable 
substrate is assumed to consist of relatively simple molecules that may be taken in 
directly by heterotrophic organisms and used for growth of new biomass. On the 
contrary, the slowly biodegradable substrate consists of relatively complex molecules 
that require enzymatic breakdown prior to utilisation. 
• Finally, heterotrophic biomass (XBH) and autotrophic biomass (XBA) are 
generated by growth on the readily biodegradable substrate (SS) or by growth on 
ammonia nitrogen (SNH). The biomass is lost via the decay process where is it 
converted to XP and XS  
Summarising, the total COD balance of ASM1 is defined by the following equation:  
CODtot = SI + SS + XI + XS + XBH + XBA + XP               
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2.4.5. Ultrafiltration 
Particles in wastewater have conveniently been grouped into operational size 
categories, namely dissolved (˂1 nm), colloidal (1-10³ nm) and settelable  (˃105 nm). 
Ultrafiltration, among other methods, is successfully used to identify and 
differentiate wastewater pollutants within much narrower ranges (Engstrom and 
Gytel, 2000; Sophonsiri and Morgenroth, 2004; Doğruel et al,2006). Particle Size 
Distribution (PSD)-based COD fractionation has been proposed and used 
successfully as an alternative approach for characterisation of municipal, industrial, 
agricultural waste streams (Sophonsiri and Morgenroth, 2004),domestic wastewaters 
(Dülekgurgen et al., 2006) with a suggestion of providing a more in-depth 
comprehension in terms of COD fractions and their biodegradability characteristics 
in relation to particle size categories.   
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3. MATERIALS AND METHODS 
3.1.General Information About the Investigated Plant 
The plant had been builded and started production on 1992. 763 personnel work, 447 
of them (%59) work in 3 shift order. Total area is 338000 m².Total capacity is 
425000 billions of packages in 3 shift and 6 days/week order. 
3.1.1.Wastewater Produced per Drug Produced 
Wastewater created in the investigated plant is given on the Table 3.1. 
Table 3.1. Wastewater generation of the investigated plant for 2012. 
Month Wastewater 
entering 
treatment system 
(m³) 
Total Discharged 
Wastewater from 
the System 
(m³) 
January 6598 9237 
February 6349 8824 
March 6946 9242 
April 6567 8593 
May 6686 8338 
June 6606 8529 
July 1730 5009 
August 5598 7400 
September 5876 7314 
October 5614 7268 
November 6374 7843 
December 6594 7902 
Total 71538 95499 
                
The investigated plant have produced 244000000 packages of drug in 2012 and 
created 95499 m³ wastewater discharged. 391 cm³ wastewater was produced per 
package of drug. 
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3.1.2.Drug Production in the Investigated Plant 
The investigated plant have production activity in the formulation subcategory.There 
is high productive activity and many kind of different drug dosages and types  are 
produced. The production units are given in Figure 3.1. 
General Drugs Beta Lactam Drugs
Solid Liquid Pomade Penicilin Cephalosporin
Tablet
Film Coated Tablet
Capsule
Powder and 
Granules
Sterile (Ampule and 
flacon)
Non-Sterile
Pomades and 
Creams
Suporizituvar
Tablet
Film Coated Tablet
Powder
Syrup and 
suspensions
Tablet
Film Coated Tablet
Powder
Capsules
Steril Powders
Syrup
Suspansion
Emulsion
Nasal Spray
Gels
Figure 3.1. The production units of the investigated plant. 
The percentage quantities of these forms are given on Table 3.2. 
Table3.2. Production forms by percentage quantities 2011 and 2012. 
 2011 % 2012 % 
Solid 47.7 50.1 
Liquid 25.0 23.0 
Pomade 9.0 8.4 
Beta Lactams 18.2 18.6 
The investigated plant production capacity and the proposed production plans until 
2016  is given at the Figure 3.2. 
In 2011, 1560000000  packages of medicine was produced in Turkey. Investigated 
plant has produced  231000000 packages in 2011. With this values, The plant have 
produced %14.8 of all the medicines produced in Turkey. Plant production capacity 
and the proposed production plans 2010-2016 is shown on Figure 3.2. 
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Figure 3.2. Plant production capacity and the proposed production plans 2010-2016. 
3.1.3. Market Share of the Investigated Plant 
The investigated firm is 18. biggest pharmaceutical firm with endorsement of 
268927780 TL in Turkey (Türkiye İlaç Sanayi Meclisi Sektör Raporu-2011) 
3.1.4. Process Schemes of the Investigated Plant 
3.1.4.1. Solid production unit and process scheme 
Solid production involves tablet preparation, printing and packaging.After raw 
material mixing, preparation is given into paste machine.Then granulation and drying 
steps are followed.If necessary cracking machines are used and the products are put 
into the printing machines.Finally packaging machines are used to package the drugs. 
Solid Production Unit and Process Scheme is given on Figure 3.3. 
3.1.4.2.Pomade production unit and process scheme 
Pomade production involves melting and mixing of the raw materials in 
cauldron.Prepared pomade is taken to the filling machine. 
Pomade Production Unit and Process Scheme is given on Figure 3.4. 
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Pre-mixing/Grinding
Raw Material Wighing
Final Mixing
Capsule Filling
Mx Filling or Glass Filling
Blistering or Glass Filling
Blistering or Glass Filling
Packaging/Boxing
      Granulation:
 Pre-wetting of some raw materials for lumping
 Drying of lumps
 Grinding of raw materials to desired form
Tablet Printing Coating
 
Figure 3.3. Solid Production Unit and Process Scheme. 
                           
Raw Material weighing Mixing Straining if required
Packaging/Boxing Tube filling or small glass filling
 
                       Figure 3.4. Pomade Production Unit and Process Scheme 
3.1.4.3. Non-sterile production unit and process scheme 
Non-sterile production  involves raw material weighing, addition to cauldron, and 
filtering steps.Prepared solution is filled to glasses in liquid filling line and packaged. 
Non-Sterile Production Unit and Process Scheme is given on Figure 3.5. 
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Raw Material WEighing Production Cauldron Pump
Liquid Filling Line Pre and Final FilterStock Cauldron
Glass Filling Packaging
 
Figure 3.5. Non-Sterile Production Unit and Process Scheme. 
3.1.4.4. Sterile liquid production unit and process scheme 
Liquid production starts with suspension preparation.Raw materials and water is put 
to the cauldrons that have heating and mixing capacity.Prepared suspensions are 
taken to waiting cauldrons and than to the filling machines.Ampulles/Flacones are 
than autoclaved.After sterilization, all units are optically controlled for 
particles.After leak control, they‘re packaged. Sterile Production Unit and Process 
Scheme is given on Figure 3.6. 
Raw Material Weighing Production Cauldron Pump
Ampulle/Flacon Filling Line Filter (0.2 micron)
Autoclave
(Sterilization)
Optic Control Leak Control Packaging
 
Figure 3.6. Sterile Liquid Production Unit and Process Scheme. 
3.1.4.5. Cephalosporin non-sterile production unit and process scheme 
Raw materials are weighed and after grinding/granulation steps they‘re 
mixed.According to final requested form, they‘re filled to capsules, mediflex / glass 
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containers or they‘re coated if final form will be tablette. Cephalosporin Non-Sterile 
Production Unit and Process Scheme is given on Figure 3.7. 
Pre-weighing/Grinding
Raw Material Weighing
Final Mixing
Filling to Capsules
Mx Filling or Glass Filling
Blistering or Glass Filling
Blistering or Glass Filling
Packaging / Boxing
      Granulation:
 Pre-wetting of some raw materials for lumping
 Drying of lumps
 Grinding of raw materials to desired form
Tablet Printing Coating
 
Figure 3.7. Cephalosporin Non-Sterile Production Unit and Process Scheme. 
3.1.4.6. Cephalosporin sterile production unit and process scheme 
For sterilization process, first flacons are washed and given to sterilization tunnel to 
be autoclaved.After sterilization, they‘re filled and capsized.After optical control, 
they‘re washed, coded, labeled, boxed, packaged and transported to warehouse. 
Cephalosporin Sterile Production Unit and Process Scheme is shown on Figure 3.8. 
3.1.4.7. Penicillin production unit and process scheme 
Raw materials are weighed and after grinding/granulation steps they‘re 
mixed.According to final requested form, they‘re filled to capsules, mediflex / glass 
containers or they‘re coated if final form will be tablette. 
Penicillin Production Unit and Process Scheme is shown on Figure 3.9. 
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Flacon Flacon Washing Sterilization Tunnel
UV Lock
Autoclave
Filling
Putting on Flacon 
Caps
Optic Control
Flacon Outer 
Washing
CoddingLabellingBoxingPackagingFinal Product
Cephalosporin 
Warehouse
 
 
Figure 3.8. Cephalosporin Sterile Production Unit and Process Scheme. 
 
Pre-weighing/Grinding
Raw Material Weighing
Final Mixing
Filling to Capsules
Mx Filling or Glass Filling
Blistering or Glass Filling
Blistering or Glass Filling
Packaging / Boxing
      Granulation:
 Pre-wetting of some raw materials for lumping
 Drying of lumps
 Grinding of raw materials to desired form
Tablet Printing Coating
 
Figure 3.9. Penicillin Production Unit and Process Scheme. 
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3.1.5. Wastewater Characterization of the Investigated Plant 
The investigated plant is in the Mixing, Compounding, Formulating subcategory.  
Wastewater generation is from two different sources: Domestic and industrial 
wastewaters.  
Wastewater characterization of the plant was examined on results section in detail. 
3.1.6. Wastewater Treatment System in The Investigated Plant 
Schematic representation of the Wastewater Treatment System is shown on Fig.3.10. 
 
Figure 3.10. Schematic Representation of the Wastewater Treatment System. 
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Two types of wastewater is come out from the investigated plant. Each of them 
reaches to treatment system with seperate channel systems.  
a. Process Wastewater : 
Industrial wastewater : Wastewater produced after the cleaning of the cauldron 
with water before the next production process.Besides, laboratory and water system 
wastewater are belong to the same group. 
Water system wastewater : Steam boiler, cooling system, water clearance 
(softener), de-ionizer and distilled water equipment and water from reverse washing. 
b.Domestic wastewater :  
Wastewater produced from human daily life needs and usage.Domestic wastewater 
and industrial wastewater enters and mixed in mixing pool, as shown in Figure 3.11. 
Two types of treatment is applied to the wastewater reaches to treatment system: 
 Chemical Treatment  
 Biological Treatment. 
 Before these processes, pre-treatment is applied to wastewater. 
Pre-treatment : 
Process wastewater is passed from screens to stability pool.These screens are used to 
hold the big pieces before they reach to the tanks. 
The chemical or chemical wastewater which can give harm to treatment system 
according to  ÇGY-04.05 Regulation on the Control Hazardous Waste are taken to 
dangerous stuff tank.They are collected and aerated for decaying. Later, they‘re 
transferred to stability pool and the process continiues. 
Wastewater taken to stability pool is aerated to be homogenized.Stabilized 
wastewater is pumped to chemical treatment pool with flow of 20 m³/h. If the 
chemical treatment is not used than this step is skipped, wastewater is pumped out to 
the neutralization pool. Neutralization pool is shown on Figure 3.12. 
Chemical treatment (Primary treatment) :  
This process is not applied since suspended solid is always below 1500 ppm. 
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      Biological treatment (Secondary treatment) : 
With this process, required wastewater discharge values are obtained.  
 
Figure 3.11. Domestic and Industrial Wastewater Entries to Mixing Pool. 
               
 
Figure 3.12. Neutralization  Pool. 
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Biological treatment reactors : 
2 reactors are used for biological treatment. Figure 3.13.shows one of the biological 
treatment reactors. These are SBR (sequencing batch reactor), each of them have 675 
m³ volumes, cylindirical and reinforced concrete. Each of them has one aerator.  
Aerator process : 
There is one aerator in each aerator.They‘re used to mix the water in reactor to 
maintain homogenicity.Working of aerators in low or high motion provides 
dissolving of oxygen in air to a certain extent (2-4 ppm).At this instant, 
organotrophic bacteria which are in activated sludge decays organic material and turn 
them to water and carbondioxide.Figure 3.14. shows the working mode of aerators in 
biological reactor. 
Application of biological treatment process : 
                  
 
 
                                    Figure 3.13. Biological Treatment Reactor . 
 
Water feeding to reactors for biological treatment is done from mixing tank.Process 
waste water is taken to neutralization pool and pH arrangement is done.After 
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neutralization process, it‘s transferred to mixing pool and mixed with domestic 
wastewater there.  
 During transfer of wastewater to reactors, care is given for pH not to be out of 
efficient range for biological treatment.pH must be  6,5 - 8,5 in reactor. 
 Working of reactors involves 4 steps, these steps are controlled and arranged 
from control panel. 
- Fill Time 
- React Time 
- Settle Time 
                         - Idle Time for Effluent Withdrawal 
Total Cycle Time= Fill Time+React Time+Settle Time+ Idle Time for Effluent 
Withdrawal    
 
Figure 3.14. Biological Treatment Reactor (aerators in working mode). 
 Fill  time: Each Reactor is fed with wastewater for 12 hours everyday. 
 React time: During this step aerators are controlled. During reaction time 1 
liter sample is taken and controlled for amount of sludge in İmhoff Cone. 
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(once a week from each reactor) (max. 200 ml/Lt). Dissolved oxygen in 
reactors is measured with portable oxygenmeter everyday and recorded. 
 Settle time: During this step buoy is controlled.After water feeding is 
completed, aerator is stopped after 6 hours and rested for 2 hours to 
precipitation of bacteria as an active sludge.In rest of time, transparent upper 
water shell appears.  
 Idle time for effluent withdrawal: After precipitation step (4 hours) 
tranparant water is transferred with floating sluice and pumped to sand filters.  
 This transparent water is tested for pH, BOD, SS 
 After precipitation step, electrical ventil is opened with signal coming from 
time relay.Then, filtration pumps start to work and treated water is sent to 
sand filters.  
 When the level in SBR comes to low position,electrical ventil is closed with 
the signal and pumps are out of session and process is completed. 
 Flow is recorded daily and treated water amount is calculated. 
Withdrawn of sludge from reactors : 
Wastes occured during biological treatment are accumulated as sludge at the 
bottom of the reactors. This sludge is emptied periodically according to Imhoff 
test made once a week.  
       Sludge treatment and filter press process : 
Sludge taken from reactors are dehydrated by filter press (water 
max.%65).Excess sludge is pumped to sludge condensation tank. Accumulated 
biological and chemical sludges are pumped to filter press and stay as a sludge 
cake after an enough dehydration (%35-45).  
Advance treatment (Tertiary treatment) : 
Sand filters are used for an advanced treatment. Biologically treated outlet water 
are pumped to sand filters with outlet pumps.  
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Sand filter usage and back wash : 
For filtration before discharge, mixed bed sand filters are used.Outlet water comes 
from sand filters are transferred to reverse wash tank. After accumulation in this 
tank, they‘re discharged to stream bed. 
3.2. Wastewater Treatment  Standards in Turkey 
Wastewater Treatment  Standards in Turkey according to Water Pollution Control 
Regulation is shown on Table 3.3. 
Table 3.3. Wastewater Treatment  Standards in Turkey ,Sector: Chemical Industry 
(Pharmaceutical Production and Similars). 
 PARAMETER UNIT 
REFERANCE MOMENTARY 
OR 2 HOURS COMPOSITE 
SAMPLE 
Chemical Oxygen Demand (COD) 
Oil and Grease 
Total Organic Carbon (TOC) 
Phenols* 
(mg/L) 
(mg/L) 
(mg/L) 
(mg/L) 
150 
10 
5 
0.3 
Fish Bioexperiment (ZSF) - 6 
pH - 6-9 
* (4-Chloro-3-methylphenol,  2-Chlorophenol,  2,4-Dichlorophenol, 2,4-Dimethylphenol, 2-Methylphenol (o-
Cresol), 3-Methylphenol (m-Cresol), 4-Methylphenol (p-Cresol), 2,4-Dinitrophenol,  2-Methyl-4,6-dinitrophenol, 
2-Nitrophenol,  4-Nitrophenol , Pentachlorophenol , Phenol,  2,4,6-Trichlorophenol total amount is measured)                                                                                                                  
(Draft SKKYEK)  
3.3. Conventional Wastewater Characterization 
COD was measured according to ISO6060 method [ISO6060, 1986]. For soluble 
COD determination, samples were subjected to vacuum filtration by means of 
Millipore membrane filters with a pore size of 0.45 µm. Other experiments were 
performed according to the Standard Methods [Standard Methods, 2005]. The 
Millipore AP40 glass fiber filters were used for total suspended solids (TSS) and 
volatile suspended solids (VSS) measurements. 
3.4. Respirometric Biodegradation Test 
The respirometric tests were conducted with acclimated biomass sampled from 
activated sludge unit of the wastewater treatment plant. Batch respirometric (OUR) 
experiment was conducted at desired initial Food/Microorganism (So/Xo) ratio. The 
OUR measurements were performed with Applitek Ra-Combo continuous 
respirometer with PC connection. A nitrification inhibitor (Formula 2533
TM
, Hach 
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Company) was added to the reactors to prevent possible interference induced by 
nitrification. The biomass and wastewater mixture was continuously aerated with 
compressed air in order to keep the dissolved oxygen level above 5 mgO2/L in the 
aeration vessel. The respirometric test was performed with approximately 2.3 times 
diluted wastewater sample. After observing the endogenous OUR level, a wastewater 
sample is added to mixed liquor having 6630 mgVSS/L was added in order to 
maintain initial substrate to biomass (So/Xo) ratio at 0.062 gCOD/gVSS.day. The 
model parameters were estimated in accordance with the method proposed by [Insel 
et al., 2003 and Dochain et al., 1997]. Model simulations and parameter estimation 
works were performed using AQUASIM program [Reichert et al., 1998]. Figure 3.15 
shows Applitek Ra-Combo continuous respirometer 
 
 
                  Figure 3.15 Applitek Ra-Combo continuous respirometer. 
3.5. Particle Size Distribution Analysis  
Filtration/Ultrafiltration experiments were conducted under positive pressure (0.6-1.2 
atm;N2 as the inert gas), in a continiously-stirred cellwith a volumetric capacity of 
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400 ml (Amicon,Model 8400).A final volume of 100 ml. permeate was determined to 
be sufficient to run COD experiments in duplicates.Samples were filtered 
sequentially through conventional filters with pore sizes of 1200-1600 nm(Millipore 
AP40, glass fiber),450 nm (Durapore HV, polyvinylidene flüoride (PVDF) and 220 
nm(Durapore GV, PVDF)(Millipore Corp, Bedford, MA 01730).The working 
pressure was kept at 0.35 atm throughout the filtration experiments with disposable 
filters.during the ultrafiltration experiments , permeates from 220 nm membrane 
filter were filtered successively through ultrafiltration  membranes with nominal 
molecular weigt cut-off (MWCO) values of 100,30,10,3 and 1 kDa (PL series , 
Millipore,MA).All experiments were conducted at room temperature and at a pH 
range of 7.2 -8.8.The pressure applied to the 100 kDa ultrafiltration membrane discs 
was 0.6 atm, and to the others was 1.2 atm (values all below the ones recommended 
by the manufacturer) 
 
 Fig.3.16. Schematic presentation of the sequential filtration/ultrafiltration procedure. 
 ( 1—Non-settled, nonfiltered,but mixed original sample, 2—aliquot of filtrate from the previous step, subjected to COD  
measurements, 3—aliquot of filtrate from the previous step, subjected to subsequent filtration/ultrafiltration procedure, 4—gas 
line providing positive pressure.  
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4. RESULTS 
4.1.Wastewater Generation of the Plant: 
The investigated plant had been observed throughout the year (2012) to reflect the 
relation between the drug produced and wastewater generated.The plant uses water 
for both production and domestic purposes. Table 4.1. shows Wastewater Generation 
of the Plant in 2012 and Figure 4.1. shows the volumes of industrial and discharged 
wastewater in 2012.As seen from the table , 23961 m³ water was used for domestic 
purposes by 763 personnel. 86 L of  domestic wastewater was created per person 
each day. 
                         Table 4.1. Wastewater Generation of the Plant for 2012. 
 
            
As seen on the table and graph, wastewater values had their lowest values on 
July.This sharp decrease of wastewater volume  was because of production shut-
down period which took 3 weeks and done each year for maintenance and repair 
purposes in production area. 
DATE 
TOTAL 
INDUSTRIAL 
WASTEWATER 
TOTAL 
DISCHARGED 
WASTEWATER  
 
Wastewater  (m³) 
Discharged Wastewater 
(m³) 
JANUARY 6598 9237 
FEBRUARY 6349 8824 
MARCH 6946 9242 
APRIL 6567 8593 
MAY 6686 8338 
JUNE 6606 8529 
JULY 1730 5009 
AUGUST 5598 7400 
SEPTEMBER 5876 7314 
OCTOBER 5614 7268 
NOVEMBER 6374 7843 
DECEMBER 6594 7902 
TOTAL 71538 95499 
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Figure 4.1. Schematic Representation of Industrial and Total Wastewater Produced. 
4.1.1.Process Profile of the Plant 
As shown in Table 4.1., wastewater  generation of the plant for 2012 is  95500 
m³/day.Total drug production is 244000000 packages/year. According to these 
values, 391 m³ wastewater is generated per package of drugs. 
4.1.2.Pollution Profile of the Plant 
Characterization of pollution profile is given on Table 4.2. Wastewater Treatment 
Results for the Investigated Plant - 2012 
As represented on Table 4.2. , average COD level for 2012 is 902 mg/l..   The plant 
have generated 236 kg COD/day  Considering the production of 244000000 
packages of drug per year, 0.35 mg/L COD was generated per packages of drug. 
4.1.3.Wastewater Treatment Results for the Investigated Plant – 2012 
Wastewater treatment results for 2012 are given on the Table 4.2. on a monthly 
averaged basis. Wastewater generations, COD , BOD, pH, SS and Sludge production 
values are measured and followed regularly. From the data, treatment efficiencies 
can be followed, also control of meeting the standards of  Water Pollution Control 
Regulation is possible. 
 
        Wastewater Volumes for  2012  
TotalDis.ww m³ 
m³ 
Indus.WW m³ 
  
  
  
  
  
W
as
te
w
w
at
er
 m
³ 
Jan   Feb       Mar    Apr    May    June   July    Aug      Sep       Oct       
Nov    Dec 
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Table 4.2. Wastewater Treatment Results for the Investigated Plant – 2012. 
 
MONTHS 
Working 
Day 
Total 
Disharged 
Water 
Industrial WW Domestic WW pH 
Chemical Oxygen Demand 
(COD) 
Biological Oxygen 
Demand(BOD) 
Suspended 
Solids(SS) 
Filtered 
Solids 
Monthly 
m³ 
Daily 
m³ 
Monthly 
m³ 
Daily 
m³ 
Monthly 
m³ 
Daily 
m³ 
Influent Effluent 
Influ. 
(mg/l) 
Efflu. 
(mg/l) 
Effic. 
Influ. 
(mg/l) 
Efflu. 
(mg/l) 
Effic. mg/l 
Sludge 
Weight Kg 
- - - - - - (6-9) 
(6.5-
8.5) 
- <100 - - <30 - <25 - 
JANUARY 
31 9237 298 6598 213 2639 85 7.42 8.04 684 34 95 360 6.15 98 5.65 3600 
FEBRUARY 
28 8824 315 6349 227 2475 88 7.28 7.86 798 57 93 320 6.67 98 4.25 4200 
MARCH 
31 9242 298 6946 224 2296 74 7.13 7.74 1208 95 92 440 2.07 100 8.48 5400 
APRIL 
30 8593 286 6567 219 2026 68 7.63 7.60 779 48 94 600 9.46 98 3.30 6000 
MAY 
31 8338 269 6686 216 1652 53 7.48 7.69 833 52 94 300 12.96 96 5.50 5400 
JUNE 
30 8529 284 6606 220 1923 64 7.21 7.74 1298 78 94 480 13.48 97 4.58 5400 
JULY 
31 5009 162 1730 56 3279 106 7.67 7.75 862 61 93 300 14.27 95 4.65 2200 
AUGUST 
31 7400 239 5598 181 1802 58 7.52 7.78 991 52 95 520 9.04 98 6.73 3000 
SEPTEMBER 
30 7314 244 5876 196 1438 48 7.42 7.71 786 25 97 520 6.15 99 3.58 4200 
OCTOBER 
31 7268 234 5614 181 1654 53 7.56 7.68 698 44 94 440 10.08 98 3.64 3600 
NOVEMBER 
30 7843 261 6374 212 1469 49 7.55 7.57 1310 63 95 360 9.48 97 6.40 5400 
DECEMBER 
31 7902 255 6594 213 1308 42 7.55 7.36 577 44 92 320 8.77 97 3.20 4800 
 
 
AVERAGE 
Total 
365 
 
7958 
+/- 
1161 
 
262
+/- 
41 
5962 
+/- 
1400 
196
+/- 
47 
1997 
+/- 
582 
66 
+/- 
19 
7.45 
+/- 
0,16 
7.71 
+/- 
0,16 
902 
+/- 
246 
54 
+/- 
19 
94 
+/- 
1,35 
413 
+/- 
101 
9.05 
+/- 
3,5 
98 
+/- 
1,22 
5.00 
+/- 
1,61 
4433 
+/- 
1163 
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Considering the discharge standards based on Water Pollution Control Regulation 
(Table 3.3), effluent COD parameter must be below 150 mg/L. To meet this criteria, 
%85 treatment efficiency must be reached. As seen from the table, treatment system 
efficiency was  %94 which meets the criteria. pH is also considered as one of the 
effluent parameters.Average pH of the effluent was 7.71. 6-9  range was expected to 
meet the criteria, which was acceptable according to regulations. 
Figure 4.2. represents  Suspended Solid Results of  Biological Treatment System for 
2012.  As seen from the graph, SS values varies between 3-9 mg/L, on average 5 
mg/L. These values are low as expected from the filtration process                .
 
Fig. 4.2.Biological Treatment System SS values for 2012. 
 
Figure 4.3. represents treatment system sludge amounts. The lowest value is on July 
as expected from the shut-down period. 3000-6000 kg of sludge produced on other 
months which differs according to type and amount of drug produced. Total sludge 
production is around 50.000 kg/year. 
   
              Fig.4.3. Biological Treatment System Sludge Values for 2012. 
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Figure 4.4. represents pH values of treatment system.pH values are around 7-8 for 
both influents and effluents. These results meet WPCR criteria.Conventional 
characterization experiments also gave similar results (6.96 and 7.04) 
 
 
Figure 4.4. Biological Treatment System pH values for 2012. 
4.2.Experimental Results 
4.2.1.Conventional Characterization  
An influent grab sample from the equalization tank  and an effluent grab sample 
from the SBR of the biological WWTP of the pharmaceutical mill (expalined in 
detail  on section 3.1.6), were collected during spring and summer seasons for 
conventional characterization. 
Total COD (mg/L),Soluble COD (mg/L),TOC (mg/L),DOC (mg/L),TSS (mg/L),VSS 
(mg/L),TKN (mg/L),NH3-N (mg/L) ,TP (mg/L),OP (mg/L),pH,Alkalinity (mg 
CaCO3/L),Cl- (mg/L),SO42- (mg/L)  analysis were performed on the samples. 
Table 4.3. represents the values found in conventional characterization studies for the 
sample taken on April 2012. 
Table 4.4. represents the values found in conventional characterization studies taken 
on June 2012. 
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               Table.4.3.Conventional Characterization Experimental results for Sample1.  
Parameter 
April 2012 
Influent Effluent 
Total COD (mg/L) 790 80 
Soluble COD (mg/L) 485 65 
TOC (mg/L) 225 25 
DOC (mg/L) 140 20 
TSS (mg/L) 200 20 
VSS (mg/L) 190 20 
TKN (mg/L) 55 25 
NH3-N (mg/L) 30 20 
TP (mg/L) 7 2 
OP (mg/L) 3 1 
pH 6.75 6.96 
Alkalinity mgCaCO3/L) 65 75 
Cl
-
 (mg/L) 120 100 
SO4
2-
 (mg/L) 100 85 
 
As seen from the results of the two samples, average COD level is 900 mg/L. This 
level is concordant with the literature for pharmaceutical industry (Çokgör et 
al,2004)  
 Soluble  COD level is 475 mg/L which is %55 of total COD. TSS are mainly 
volatile. 
COD/TOC ratio is 3.67 . TKN, 60 mg/L and TP , 8 mg/L on average is similar to 
domestic wastewater (around 50 mg/L for TKN, 10 mg/L for TP, Orhon et al, 
2009)Experimental data reveal an overall COD removal efficiency of %90 for the 
investigated pharmaceutical wastewater. This value meets acceptance criteria of 
Water Pollution Control Regulation. Biological treatment yielded satisfactory 
removal efficiencies for all parameters. COD removal efficiency results are also 
concordant with the plant‘s measurements.(%94 COD removal efficiency) 
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Table 4.4. Conventional Characterization Experimental results for Sample 2. 
Parameter 
June 2012 
Influent Effluent 
Total COD (mg/L) 945 120 
Soluble COD (mg/L) 465 95 
TOC (mg/L) 265 35 
DOC (mg/L) 135 30 
TSS (mg/L) 350 20 
VSS (mg/L) 330 20 
TKN (mg/L) 65 30 
NH3-N (mg/L) 40 30 
TP (mg/L) 9 3 
OP (mg/L) 4 1 
pH 6.94 7.05 
Alkalinity (mgCaCO3/L) 85 90 
Cl
-
 (mg/L) 145 120 
SO4
2-
 (mg/L) 120 100 
 
4.2.2.Respirometric Test Results - Date 21.06.2012 
The respirometric tests were conducted with acclimated biomass sampled from 
activated sludge unit of the wastewater treatment plant. The biomass and wastewater 
mixture was continuously aerated with compressed air in order to keep the dissolved 
oxygen level above 5 mgO2/L in the aeration vessel. The respirometric test was 
performed with approximately 2.3 times diluted wastewater sample. After observing 
the endogenous OUR level, a wastewater sample is added to mixed liquor having 
6630 mgVSS/L was added in order to maintain initial substrate to biomass (So/Xo) 
ratio at 0.062 gCOD/gVSS.day. The results of the respirometric measurements of 
OUR and Soluble COD are given on Table 4.5.  
Respirometric tests were performed with relevant acclimated biomass  seeding alone 
to obtain the level of initial endogenous oxygen uptake rate (OUR). 
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Table 4.5. Respirometric Measurements of OUR and Soluble COD. 
Parameter Value Unit 
VSludge 1000 mL 
VTap Water 300 mL 
VWW 1000 mL 
Time (min) Time OUR (mg/L/h) 
Soluble 
COD (mg/L) 
0 09:12 119.0 210 
29 09:41 28.6 76 
59 10:11 23.6 66 
119 11:11 16.7 54 
150 11:42 end. resp. level 38 
 
Determination of endogenous respiration rate of the biomass sample, was the first 
step of respirometric measurements.After the endogenous respiration rate was stabile 
for half an hour, main respirometry reactor  was fed up with wastewater that was 
filtered from 0.45 μm membrane filter in a way that F/M ratio was 0.03 COD/g VSS. 
At the beginning, very high OTH Profile was observed due to the consumption of 
readily biodegradable COD component. According to the method that was used to 
determine the readily biodegradable COD component by Ekama et al (1986), the 
concentration of readily biodegradable COD concentration was found from the area 
of time segment  until clear and instant decrease was seen. OUR Profiles of 
respirometric measurements conducted on soluble wastewater samples was shown on 
Figure 4.11. COD measurements conducted on samples taken from respirometer on 
selected times were shown on Figure 4.12. 
4.2.3.Ultrafiltration  
In this study , Particle size distribution (PSD) via sequential filtration/ultrafiltration 
was used as the tool for COD fractionation of  pharmaceutical company wastewaters 
before and after treatment. 
Treatment efficiency were determined via comparing the profiles of the effluents 
from biological-treatment to those of the corresponding influents. Particle Size 
Distribution (PSD) analysis was used by means of sequential filtration and 
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ultrafiltration, to attain a better image of distribution of organic carbon content, thus 
the COD fingerprint, of the investigated pharmaceutical  wastewater. For that 
purpose, influent and effluent samples were collected from the biological treatment 
system  of the investigated plant , and sequential filtration/ ultrafiltration experiments 
were executed to obtain the PSD-based profiles for the samples. Profiles obtained for 
the influents and effluents have revealed COD  characteristics for the wastewaters.  
Comparison of influent and effluent  profiles described the specific impact of applied 
treatment processes on distribution of COD fractions.  
The cumulative values for a given filter size indicate the  COD of the permeate and 
thus, each one describes the total COD below the selected filter size. The differential 
COD between the two consecutive filter sizes can then be calculated as the difference 
between the two relevant absolute CODs. The first values seen in the table 
correspond to the total COD contents (sum of particulate, settleable and 
supracolloidal, colloidal, and soluble portions) of the samples. The profiles for the 
effluents, when compared with those of the influents, roughly imply the treatment 
efficiencies. 
Tables and Figures below represents Filtration/Sequential Filtration results, PSD 
Analysis, Percent COD Distribution and Percentage contributions from each size 
interval for the 2 wastewater samples taken before and after the biological treatment. 
Results of Sample 1: 
Table 4.6 . Cumulative and differential COD values of pharmaceutical wastewater 
before and after biological treatment. 
Separation 
Technique 
Particle 
size 
(nm) 
Cumulative COD 
(mg/L) Size 
Category 
(nm) 
Differential COD 
(mg/L) 
Biological Treatment Biological Treatment 
Influent Effluent Influent Effluent 
Total  790 80    
Filtration       
AP40 filter 1600 605 70 > 1600 185 10 
HV filter 450 485 65 450-1600 120 5 
GV filter 220 465 65 220-450 20 0 
Ultrafiltration       
100 kDa 13 355 65 13-220 110 0 
30 kDa 8 340 65 8-13 15 0 
10 kDa 5 330 60 5-8 10 5 
3 kDa 3 305 60 3-5 25 0 
1 kDa 2 285 55 2-3 20 5 
    < 2 285 55 
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Figure 4.5. Particle size distribution of COD before and after biological treatment. 
 
 
 
 
Figure 4.6.  Percent COD distribution of the pharmaceutical wastewater before and 
after biological treatment. 
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Figure 4.7. Percentage contributions from each size interval before and after 
biological treatment. 
 
 
Results of Sample 2: 
Table 4.7. Cumulative and differential COD values of pharmaceutical wastewater 
before and    after biological treatment. 
Separation 
Technique 
Particle size 
(nm) 
Cumulative COD (mg/L) 
Size Category 
(nm) 
Differential COD 
(mg/L) 
Biological Treatment Biological Treatment 
Influent Effluent Influent Effluent 
Total  945 120    
Filtration       
AP40 filter 1600 590 105 > 1600 355 15 
HV filter 450 465 95 450-1600 125 10 
GV filter 220 445 95 220-450 20 0 
Ultrafiltration       
100 kDa 13 330 95 13-220 115 0 
30 kDa 8 320 95 8-13 10 0 
10 kDa 5 315 85 5-8 5 10 
3 kDa 3 280 85 3-5 35 0 
1 kDa 2 260 80 2-3 20 5 
    < 2 260 80 
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Figure 4.8. Particle size distribution of COD before and after biological treatment. 
 
 
 
 
 
 
Figure 4.9. Percent COD distribution of the pharmaceutical wastewater before and 
after biological treatment. 
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   Figure 4.10. Percentage contributions from each size interval before and after 
biological treatment. 
 
As seen from the results; COD fingerprints of 2 influent samples taken were quite 
similar  at all the  size ranges; with the settleable fraction (˃nm) and soluble fraction 
(˂2 nm)  being the most apparent ones. Whereas for effluents only the soluble 
fractions are apparent. Biological treatment was effective at both ends of size 
distribution, with almost total removal at the particulate range and most of the 
soluble portion. Biological treatment was successful in removing all size ranges 
except soluble  inert COD fraction. 
It was concluded that the COD content of the effluents accumulating at the ˂2 nm 
size interval was mostly due to initial soluble inert COD by-passing treatment and 
soluble inert microbial products being generated in the course of biological 
treatment. This can also be seen from soluble inert COD concentration results (38 
mg/L soluble COD concentration at endogenous respiration level ) measured by 
respirometer. (Table 4.5) 
4.2.4.Modeling of  Experimental Results 
In this study, the Aquasim Software was used to model the chronic experiment in order 
to determine related kinetic and stochiometric coefficients. A multicomponent model 
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referred to as Activated sludge Model (ASM1) was used in modelling studies. 
(Reichert et al, 1998). 
Modeling consist of analyzing and calibrating the OUR profiles. The calibrated model 
provided a close fit with the experimental OUR profile displayed on Fig. 4.11., 
defining the (1) relative magnitude of biodegradable COD fractions and (2) 
appropriate kinetic and stoichiometric coefficients applicable for the biodegradation 
of the pharmaceutical wastewater. The model simulation of COD data is displayed 
on Figure 4.12. The OUR experiments were started with a diluted soluble COD level 
of 210 mg/L. The calibration exercise was initiated and confirmed with an 
endogenous decay coefficient, bH, of 0.20/day, fE of 0.20, and a heterotrophic yield, 
YH, of 0.67 mg cell COD per mg COD commonly determined for similar 
evaluations. 
 
 
Figure 4.11.Model simulation of OUR data (ASM1). 
The results of the model calibration related to the assessment of kinetic and 
stoichiometric coefficients are outlined in Table 4.8. Regarding the biodegradation 
kinetics, the maximum specific growth rate, μH, associated with readily 
biodegradable COD utilization for microbial growth was defined as 6.0/day, a value 
Time, day 
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within the range of 3.5–6.5/day reported for domestic sewage (Henze et al. 2000; 
Sözen et al. 1998). The corresponding half-saturation coefficient, KS, was 30 mg 
COD/L. In general, the model evaluation reveals the biodegradable nature of the 
pharmaceutical wastewater. 
 
Figure 4.12. Model Simulation of COD data. 
Table 4.8. Results of Model Calibration.  
Model 
Parameters/State 
Variables 
Unit Value 
 
Model 
Parameters/State 
Variables 
Unit Value 
 
µHmax 1/day 6 
 
KXS2  0.1 
 
Ks mgCOD/l 30 
 
Ks mg 
COD/L 
 
30 
bH 1/day 0.2 
 
µH 
 
1/day 6 
CSin mg/COD/L 170 
 
Ssin 
 
mg COD 
/L 
24 
fE  0.2 
 
SH2 in 
 
mg 
COD/L 
66 
K h S1 1/day 
 
2.7 SH1 in 
 
mg 
COD/L 
80 
K X S1 
 
mg COD/COD 0.006 YH 
 
 0.67 
KhS2 
 
 2 XHin 
 
mg 
COD/L 
3100 
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4.3. Optimization Studies of Modeling Data and Experimental Results 
4.3.1. Estimation of  f XS = 0.28    f XI = 0.23 rate constants 
Table 4.9  shows the  results of  convantional characterization of the sample that was 
taken on June 2012. 
                       Table 4.9. Results of  Convantional Characterization of 2.sample. 
Influent Unit(mg/L) 
Total COD 945 
Sol. COD 465 
Part. COD 480 
 
With the help of respirometric measurements (OUR data), soluble COD fractions  
(SI, SS and SH ) were found as below; 
SI = 75  mg/L 
SS = 53 mg/L 
SH = 330 mg/L 
S Total =   ≈ 460 mg/L 
From these results, stochiometric coefficients can be found as below: 
f SI = %8 = SI / Total COD 
f SS = %5.6 = SS / Total COD 
f SH = %35 = SH / Total COD 
From the knowledge that the sum of these values is  %48.6 of the total COD, it can 
be predicted that the sum of  f XS (= XS / Total COD) and f XI (= XI / Total COD) is 
% 51.4. Since it‘s impossible to find Xs ve XI values seperately with experimental 
methods, trial and error method was used to find the concordant values for fXS and fXI 
with the model data. 
Since total COD is around  945 mg/L and  S Total  is around  460 mg/L  ; 
X S + X I can be found as  480 mg/L    
After several tests , concordant values were found as;  
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f XS = 0.28  and f XI = 0.23 .  
These values are applied to the model to make comparisons between measured and 
calculated values of S COD. Table 4.10 shows measured and calculated values for 
selected months and the average values. 
 Table 4.10. Comparison of measured and model S COD values.   
Date COD in (mg/L) S COD  (Effluent) 
    (mg/L) 
SCOD model (mg/L) 
(Effluent SI andSı + Sp) 
February 798 57 40 and 52 
March 1208 95 60 and 74 
April 779 48 39 and 49 
July 862 61 43 and 55 
August 991 52 50 and 61 
November 1310 63 65 and 80 
December 577 44 29 and 39 
Average 902 54 45 and 57 
*Ɵx was taken 20 on average 
As seen from the table, resulting SI and SP values (SI and SI+ SP) were close to  the 
measurements taken by the plant itself. The harmony of model values and measured 
values are higher in the months that have average COD close to the yearly average 
COD. This concordancy was not observed in all months, because the comparison 
was made with one sample but COD varies throughout the year due to many 
contributing factors. 
4.3.2.Calculation of  k Value  
f XS = 0.28    and  f XI = 0.23 values was used to calculate XS and XI values; 
X S = fXS * Total COD = 265 mg/L   
and X I = 215 mg/L    ( X S + X I = 480 mg/L ) 
With these values , biodegradable total COD: 
COD biodeg = S S + S H + X S = around 650 mg/L  (  L 0 value that will be used in BOD 
ultimate equation  ) 
Approximate BOD/COD value is found from the plant‘s measurements.  
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(for 945 mg /L COD, BOD 5 value is 435 mg/L) 
BOI 5 = Lo ( 1-e 
–k.5
) 
435 = 650 (1-e
-k5
)  equation was used to find k value of 0.22 day
-1
.
 
This value is 
similar to domestic wastewater values. 
4.3.3.Evaluation About the Aeration System  
Mechanical aerators that are used in biological treatment reactors works in slow or 
fast modes to maintain required level of oxygen. They work with  18.5 kW/hr in slow 
mode, 25 kW/hr in fast mode. 
 VT volume is 675 m
3
 
 Vo volume is  545 m
3 
(675-260/2) 
Oxygen given to system is 1.5-2.0 kg O2/kWh , on average 1.7 kg O2/kWh  
In slow mode; 
18.5 * 1 h * 1.7 = 32 kg O2/hr 
When this value is divided to VT ,  
oxygen given per m
3
 :47 mg O2/L.h 
In fast mode this value: 
25 * 1 h * 1.7 / VT = 62 mg O2/L.h 
OTR / V = kLa (CSo – CO2) 
47 = kLa ( 8-2) 
kLa = 7.83 x 24 = 188 h
-1 
(for slow mode) and  
kLa = 248 h
-1 
(for fast mode) 
Daily oxygen transfer rate is always higher than 5 mg/L 
When these results were compared to OUR data coming from the model, it is seen 
that aeration of the Biological Reactors are around 1.5 times higher than needed. 
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5. CONCLUSIONS 
In this study, the wastewaters of the pharmaceutical plant in Turkey which has a 
biological treatment system had been investigated. It is  aimed to determine the 
responses of the activated sludge culture to antibiotic substances by means of 
modelling tools which enables to determine the kinetic and stochiometric constants 
of the mixed culture. Relevant kinetic and stochiometric coefficients were achieved 
using ASM1 pattern in the study. By comparing real and calculated values, it‘s been 
aimed to propose better operational modes for more efficient treatment.  
The investigated plant produces %15 of all drugs in Turkey. With 8 different 
production lines,  in 21 different dosage forms,  around 250000000 packages of 
drugs are produced per year.  Plant produces 95000 m³ of wastewater each year for 
domestic and industrial purposes. 75000 m³ of it is used for production processes. It 
has biological treatment system having two cylindirical reactors each having 
volumes of  675 m³ with aerators. Overall COD level of the combined wastewaters 
of domestic and industrial based  is around 900 mg/L, a level which is quite 
representative for the pharmaceutical industry. 
Conventional characterization tests, particle size distribution analysis by sequential 
filtration / ultrafiltration  were conducted on both samples taken from influent and 
effluent of the biological treatment system. Respirometric analysis and modelling 
studies using Aquasim ASM1 Model were conducted on the second influent.  
Results of these tests show that COD removal efficiency of treatment is around 
%90.According to Water Pollution Control Regulation, dicharge limits for COD and 
pH levels are 150 mg/L and 6-9 respectively. Treatment system generates effluent at 
COD level of around 100 mg/L and pH of 7 as measured experimentaly.These values 
are concordant with the plant measurements and meets the Water Pollution Control 
Regulation criteria. It is concluded that aerobic biological treatment is effective and 
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sufficient for the wastewater generation of the plant.  
The results of the model calibration related to the assessment of kinetic and 
stoichiometric coefficients reveals the biodegradable nature of the pharmaceutical 
wastewater. 
From PSD analysis results it is seen that biological treatment was effective at both 
ends of size distribution, with almost total removal at the particulate range and most 
of the soluble portion. Biological treatment was successful in removing all size 
ranges except soluble  inert COD fraction.  
Results of optimization studies  of modeled and calculated data shows the 
concordancy of the both results in most of the months. Results are more adaptable for 
the months that influent CODs are more close to average COD.  
Calculated k value during optimization studies, 0.22 day
-1
; is similar to domestic 
wastewater values as expected. 
Evaluation of aeration system shows the excess aeration around 1.5 times than 
needed. This fact can be considered by the plant in the future feasibility studies. 
Finally, performing PSD-based COD fractionation of biological treatment effluents 
of various wastewaters with different characteristics should be considered as an 
interesting  issue for further research. 
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